

Guide for SMS - Jail Survey - Year 3

data migrated to Jail survey project. This project was created in error.

Project Overview

Data pulled on: 2024-12-27 01:13:53

Total number of observations: 15

All fields are counted among field types below even if they contain no data and/or are omitted from this report

radio fields: 310
descriptive fields: 270
text fields: 112
checkbox fields: 11
notes fields: 10
dropdown fields: 1

Identifier fields: 17

hcs22_jail_name, hcs22_jail_address_1, hcs22_jail_address_2, hcs22_jail_address_city, hcs22_jail_address_zip, hcs22_poc_name_first, hcs22_poc_name_last, hcs22_poc_phone, hcs22_poc_email, hcs22_poc_email_dk, hcs22_sec_name_first, hcs22_sec_name_last, hcs22_sec_role, hcs22_sec_phone, hcs22_sec_email, hcs22_sec_email_dk, hcs22_poc_comm_oth

Omitted fields (all blank): 308

hcs22_jail_name_dk, hcs22_jail_address_2, hcs22_jail_address_state_dk, hcs22_poc_name_first_dk, hcs22_poc_name_last_dk, hcs22_poc_email_dk, hcs22_sec_email_dk, hcs22_poc_comm_oth, hcs22_poc_comm_dk, ic_version, hcs22_consent_phone_2, hcs22_consent_answer, hcs22_consent_lang_phone_2, hcs22_consent_lang_web_2, consent_date, hcs22_jail_version, hcs22_state, hcs22_role, b1b_1, c1a, c1a_pnta, b2aa, b2aaa, c1a1, c1a1_pnta, b2ba, b2baa, c1a2_u, c1a2_u_pnta, b2ca, b2caa, c1c_u, c1c_u_pnta, b2da, b2daa, b3, b3_pnta, b4, b4_pnta, d1, d1a1_1, d1a1_2, d1a1_3, d1a1_4, d1a1_5, d1a99_text, d1a99_text_pnta, d1b1_1, d1b1_2, d1b1_3, d1b1_4, d1b1_5, d1b1_6, d1b1_7, d1b1_8, d1b99_text, d1b99_text_pnta, e1, e1a1_1, e1a1_2, e1a1_3, e1a1_4, e1a99_text, e1a99_text_pnta, e2, e2a1_1, e2a1_2, e2a1_3, e2a1_4, e2a99_text, e2a99_text_pnta, f1, f2, f2a2, f2b2, f2b4, f2e, f2e_pnta, e2ba, e2baa, e3, e3a, e3a_pnta, e3aa, e3aaa, f5, f5a2, f5b2, f5b4, f5e, f5e_pnta, e4ba, e4baa, f8, f8b2, f8b3, f8e, f8e_pnta, e5ba, e5baa, j2, j4, j5, j6a, j6a_pnta, f3aa, f3aaa, k1a_a, k1a_b, k1a_c, k1a_d, k1a_e, k1a_f, k1a_g, k1a_h, k1z_text, k1z_text_pnta, k2a_a, k2a_b, k2a_c, k2a_d, k2a_e, k2a_f, k2z_text, k2z_text_pnta, n7, n1, n2, n2_oth, n3, n3_oth, n4, n4_oth, n5, n5a_oth, n5both, n6, n6a, n6a_oth, n6b, n6b_oth, ic_version_y2, hcs22_consent_phone_2_y2, hcs22_consent_answer_y2, hcs22_consent_lang_phone_2_y2, hcs22_consent_lang_web_2_y2, consent_date_y2, hcs22_jail_version_y2, hcs22_state_y2, hcs22_role_y2, b1b_1_y2, c1a_y2, c1a_pnta_y2, c1a1_y2, c1a1_pnta_y2, c1a2_u_y2, c1a2_u_pnta_y2, c1c_u_y2, c1c_u_pnta_y2, b3_y2, b3_pnta_y2, b4_y2, b4_pnta_y2, ca1_y2, ca1a_y2, ca1b_y2, ca1c_y2, d1_y2, d1a1_1_y2, d1a1_2_y2, d1a1_3_y2, d1a1_4_y2, d1a1_5_y2, d1a99_text_y2, d1a99_text_pnta_y2, d1b1_1_y2, d1b1_2_y2, d1b1_3_y2, d1b1_4_y2, d1b1_5_y2, d1b1_6_y2, d1b1_7_y2, d1b1_8_y2, d1b99_text_y2, d1b99_text_pnta_y2, e1_y2, e1a1_1_y2, e1a1_2_y2, e1a1_3_y2, e1a1_4_y2, e1a99_text_y2, e1a99_text_pnta_y2, e2_y2, e2a1_1_y2, e2a1_2_y2, e2a1_3_y2, e2a1_4_y2, e2a99_text_y2, e2a99_text_pnta_y2, f1_y2, f2_y2, f2a2_y2, f2b2_y2, f2b4_y2, f2b1_y2, f2e_y2, f2e_pnta_y2, e3_y2, e3a_y2, e3a_pnta_y2, f5_y2, f5a2_y2, f5b2_y2, f5b4_y2, f5e_y2, f5e_pnta_y2, f8_y2, f8b2_y2, f8b3_y2, f8e_y2, f8e_pnta_y2, j2_y2, j4_y2, j5_y2, j6a_y2, j6a_pnta_y2, k1a_a_y2, k1a_b_y2, k1a_c_y2, k1a_d_y2, k1a_e_y2, k1a_f_y2, k1a_g_y2, k1a_h_y2, k1z_text_y2, k1z_text_pnta_y2, k2a_a_y2, k2a_b_y2, k2a_c_y2, k2a_d_y2, k2a_e_y2, k2a_f_y2, k2z_text_y2, k2z_text_pnta_y2, o1_y2, o2_y2, o2_dk_pnta_y2, o3_y2, o3_dk_pnta_y2, o4_y2, o4_dk_pnta_y2, o5_y2, o5_2_y2, o5a_oth_y2, o5b_oth_y2, o6_y2, o6a_y2, o6a_dk_pnta_y2, o6b_y2, o6b_dk_pnta_y2, n7_y2, n1_y2, n2_y2, n2_oth_y2, n3_y2, n3_oth_y2, n4_y2, n4_oth_y2, n5_y2, n5a_oth_y2, n5both_y2, n6_y2, n6a_y2, n6a_oth_y2, n6b_y2, n6b_oth_y2, hcs22_consent_phone_2_y3, c1a_pnta_y3, c1a1_pnta_y3, c1a2_u_pnta_y3, c1c_u_pnta_y3, b3_pnta_y3, b4_pnta_y3, d1a99_text_pnta_y3, e1a99_text_pnta_y3, f5e_pnta_y3, k2z_text_pnta_y3, o3_y3, o4_y3, o5a_oth_y3, o5b_oth_y3, o6b_y3, n7_y3, n1_y3, n2_y3, n2_oth_y3, n3_y3, n3_oth_y3, n4_y3, n4_oth_y3, n5_y3, n5a_oth_y3, n5both_y3, n6_y3, n6a_y3, n6a_oth_y3, n6b_y3, n6b_oth_y3

Each field in this annotated codebook gets an entry structured like this:

Field label	Field name
	Field type: (radio, text, etc) Observations with this field left blank: # Number of unique values: ## Branching logic: equation

Choice value	Label	Frequency
value1	Choice 1 label	#
value2	Choice 2 label	#
value3	Choice 3 label	#

1. Instrument: point_of_contact

Record ID (text)	record_id
Field type: text Observations with this value left blank: 0 Number of unique values: 14	

Version # (text)	hcs22_version
Field type: text Observations with this value left blank: 0 Number of unique values: 1	

Name of Jail (text)	hcs22_jail_name
Identifier & Required Field type: text Observations with this value left blank: 0 Number of unique values: 15 Branching logic: [hcs22_jail_name_dk] = "	

Address 1 (text in matrix hcs22_jail_address)	hcs22_jail_address_1
Identifier Field type: text Observations with this value left blank: 0 Number of unique values: 14	

City (text)	hcs22_jail_address_city
Identifier Field type: text Observations with this value left blank: 0 Number of unique values: 14	

State (dropdown)	hcs22_jail_address_state
Required Field type: dropdown Observations with this value left blank: 0 Number of unique values: 1 Branching logic: [hcs22_jail_address_state_dk]="	

Choice value	Label	Frequency
1	Kentucky	0
2	Massachusetts	0
3	New York	0
4	Ohio	15

Zip (text) **hcs22_jail_address_zip**

Identifier
Field type: text
Observations with this value left blank: 0
Number of unique values: 14

First name (text) **hcs22_poc_name_first**

Identifier & Required
Field type: text
Observations with this value left blank: 0
Number of unique values: 14
Branching logic: [hcs22_poc_name_first_dk] = "

Last name (text) **hcs22_poc_name_last**

Identifier & Required
Field type: text
Observations with this value left blank: 0
Number of unique values: 14
Branching logic: [hcs22_poc_name_last_dk] = "

Role (text) **hcs22_poc_role**

Field type: text
Observations with this value left blank: 0
Number of unique values: 12

Phone Number (text) **hcs22_poc_phone**

Identifier
Field type: text
Observations with this value left blank: 0
Number of unique values: 14

What is his/her email address? (text)**hcs22_poc_email**

Identifier

Field type: text

Observations with this value left blank: 0

Number of unique values: 14

First Name (text)**hcs22_sec_name_first**

Identifier

Field type: text

Observations with this value left blank: 12

Number of unique values: 3

Last Name (text)**hcs22_sec_name_last**

Identifier

Field type: text

Observations with this value left blank: 12

Number of unique values: 3

Role (text)**hcs22_sec_role**

Identifier

Field type: text

Observations with this value left blank: 12

Number of unique values: 3

Phone Number (text)**hcs22_sec_phone**

Identifier

Field type: text

Observations with this value left blank: 12

Number of unique values: 3

What is his/her email address? (text)**hcs22_sec_email**

Identifier

Field type: text

Observations with this value left blank: 12

Number of unique values: 3

Which state's HCS study are you entering data for? (radio)

hcs22_poc_state

Required
Field type: radio
Observations with this value left blank: 0
Number of unique values: 1

Choice value	Label	Frequency
1	Kentucky	0
2	Massachusetts	0
3	New York	0
4	Ohio	15

Mode of Survey (radio)

hcs22_mode_survey

Required
Field type: radio
Observations with this value left blank: 0
Number of unique values: 1

Choice value	Label	Frequency
1	By phone	0
2	Via email link	0
3	In person	15

2. Instrument: informed_consent

CONSENT TO PARTICIPATE IN A RESEARCH STUDYHCS Annual Jail Survey (descriptive)

ic_hd

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_mode_survey]='2' or [hcs22_mode_survey]='3'

CONSENT TO PARTICIPATE IN A RESEARCH STUDYHCS Annual Jail SurveyUse this verbal consent for data collection if the participant is not present in-person and the survey is conducted by phone. (descriptive)

ic_hd_phone

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_mode_survey]='1'

Sponsor / Study Title: The National Institute on Drug Abuse / "The HEALing Communities Study (HCS)" Principal Investigator: Bridget Freisthler, Ph.D. Telephone: (614) 293-4041(614) 293-8000 (24 Hours) Address: The Ohio State University-Pomerene Hall1760 Neil Avenue Suite 380Columbus, OH 43210 (descriptive)

ic_hd_contact

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_mode_survey]='2' or [hcs22_mode_survey]='3'

KEY INFORMATION We are asking you to choose whether or not to participate in the HEALing Communities Study funded by the National Institute on Drug Abuse and conducted by four academic institutions: Boston Medical Center, Columbia University, University of Kentucky, and The Ohio State University. This study uses community engagement as a means to increase the use of evidence-based approaches with the goal of reducing opioid-related mortality by 40% over the course of the research study. We are asking you to participate because as a key employee within jails associated with communities engaged in the HCS, you have information and opinions relevant to addressing the opioid

hcs22_consent_inperson

epidemic. This page gives you key information to help you decide whether to participate. We have included detailed information following this page. Ask the research study team questions. If you have questions later, the contact information for the research study investigator in charge of the study is provided above. **WHAT IS THE STUDY ABOUT AND HOW LONG WILL IT LAST?** By doing this study, we hope to learn how community coalitions can most effectively respond to the opioid epidemic and reduce opioid-related deaths. The primary study goal is to reduce the number of opioid overdose deaths by at least 40% in 67 selected communities over the next three years by working with community coalitions. Your participation in this research survey should take approximately 15 minutes and the survey is repeated once a year for the next three years. We anticipate that 200 other key jail employees will participate in this survey. **WHAT ARE KEY REASONS YOU MIGHT CHOOSE TO PARTICIPATE IN THIS STUDY?** By choosing to participate in this study, you may help to reduce the negative impacts of the opioid epidemic for individuals, families, and communities. For a complete description of benefits, refer to the Detailed Consent. **WHAT ARE KEY REASONS YOU MIGHT CHOOSE NOT TO PARTICIPATE IN THIS STUDY?** There are no foreseeable physical risks involved with this study. For a description of the potential risks, refer to the Detailed Consent. **DO YOU HAVE TO TAKE PART IN THE STUDY?** If you decide to take part in this study, it should be because you really want to participate. You will not lose any services, benefits or rights you would normally have if you choose not to participate. Your decision will not affect your relationship with your employer or the HEALing Communities Study research team. **WHOM TO CONTACT ABOUT THIS STUDY** During the study, if you have questions, concerns, or complaints about the study, please contact the Investigator at the telephone number listed on the first page of this consent document. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact: By mail: Study Participant Adviser Advarra IRB6940 Columbia Gateway Drive, Suite 110 Columbia, MD 21046 or call toll free: 877-992-4724 or by email: adviser@advarra.com Please reference the following number when contacting the Study Participant Adviser: Pro00038088. **DETAILED CONSENT: WHAT WILL YOU BE ASKED TO DO AND WHAT IS THE TOTAL AMOUNT OF TIME INVOLVED?** A number of different research study activities will be involved during different phases of the study. If you agree to be part of the study,

you will be asked to take part in a survey to ask you about the opioid-related services provided by jails in communities participating in HCS. The survey will take approximately 15 minutes to complete and will be repeated once a year for the next three years. Even if you agree to participate in the research study now, you may at any time decline to participate. Doing so will not affect your current work status, future advancement, or your relationship with the HEALing Communities Study research team.

WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? No physical risks are involved in this study. The risk of a breach in confidentiality of your study data is minimized by the procedures in place to protect your privacy. You will not be asked to provide personal information other than basic demographic information. Although we would like you to answer all the survey questions asked of you, you may choose not to answer questions without any negative consequences. There may be risks which are currently unforeseeable.

WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY? You will receive no direct benefits from participating in this research study. However, your participation could assist your community in examining procedures and improving services for individuals with opioid use disorder or at risk of opioid overdose. Your participation may also help your community by enhancing the process and communication among organizations involved.

IF YOU DON'T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER CHOICES? If you do not want to be in the study, there are no other choices except to not take part in the study.

WHAT WILL IT COST YOU TO PARTICIPATE? There is no cost to you to participate in the study.

WHO WILL SEE THE INFORMATION THAT YOU GIVE? We will make every effort to keep private all research study records that identify you to the extent allowed by law. Study data will be collected, managed, and analyzed by the four research sites and RTI International, the Data Coordinating Center located in North Carolina. Any data that are stored electronically will reside in a password-protected database on a secure server. Research records will be deidentified and stored using a secure participant identification number. These identification numbers will be used for combining data from various surveys and interviews, which will be important for analyzing the data. Your information will be combined with information from other people taking part in the study. The study investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name. This means that absolute confidentiality cannot be guaranteed. We will

publish the results of this study only in the aggregate, and you will not be identified directly or indirectly in study reports and presentations.

THIS RESEARCH STUDY IS COVERED BY A CERTIFICATE OF CONFIDENTIALITY from the National Institutes of Health. Study investigators with this Certificate may not disclose or use information or documents that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information or documents protected by this Certificate cannot be disclosed to anyone else who is not connected with the research study except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or neglect, harm to self or others, or communicable diseases), but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings; if you have consented to the disclosure; or if it is used for other scientific research, as allowed by federal regulations protecting research participants. The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the study that is needed for auditing or program evaluation by National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration, which are funding this study. You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this research study.

CAN YOU CHOOSE TO WITHDRAW FROM THE STUDY EARLY? You can choose to leave the study at any time. If you decide to take part in the study, you still have the right to decide at any time that you no longer want to continue. No one will think badly of you or treat you differently if you decide not to take part in this study. If you choose to leave the study early, data collected until that point will remain in the study database and may not be removed. The study investigator or sponsor can stop your participation at any time without your consent for the following reasons: If you fail to follow directions for participating in the study; If it is discovered that you do not meet the study requirements; If the study is canceled; or For administrative reasons. Any new important information that is discovered during the study that may influence your willingness to continue participation in the study will be given to you. You may refuse to participate, or you may withdraw from the study at any time, without penalty.

WILL YOU RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY? You will not receive compensation for completing the survey.

HOW

WILL YOUR PRIVACY AND CONFIDENTIALITY BE PROTECTED? We will take careful steps to keep your information confidential. All identifiable information (for example, your name) will be removed from the information collected in this study. We will make every effort to prevent anyone who is not on the research team from knowing that you gave us information, or what that information is. For example, your name will be kept separate from the information you give, and these two things will be stored in different places under lock and key. We will label your information with a code and will store the key separately from the master code list. Only select study staff will have access to the list that links the code to you. All research data will be kept in locked file cabinets. Computer files will be retained, and all electronic data will be password protected, stored on secure servers, and accessible only to the researchers on this study.

WILL YOUR INFORMATION BE STORED AND USED FOR FUTURE RESEARCH? All identifiable information (for example, your name, employer, and contact information) will be removed from the information collected for this study. After we remove all identifiers, the information you provide during the study may be used for analysis or shared with other researchers without your additional informed consent. The deidentified information will be stored on secure servers at the research sites and the data coordinating center at RTI International during the study. We plan to store and share deidentified data from surveys and interviews for future research. Data collected or transmitted under this study will be maintained for at least 3 years. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. Researchers can use the stored information to research additional scientific questions. There is a risk that someone could get access to the stored information. Despite the security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now.

WHAT ELSE DO YOU NEED TO KNOW? If you agree to take part in this study, you will be one of about 200 key jail employees to do so. The National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration are providing financial support for this study. A description of this clinical trial will be available on <http://www.clinicaltrials.gov/> as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results.

**You can search this Web site at any time.
(descriptive)**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='3'

Hello. My name is [name] and I work for the HEALing Communities Study (HCS) in your state. We are working with the National Institute on Drug Abuse (NIDA) and research sites in three other participating states to conduct the HEALing Communities Study. This study uses community engagement as a means to increase the use of evidence-based approaches with the goal of reducing opioid-related mortality by 40% over the course of the research study. We are conducting surveys to assess the provision of opioid use disorder related services provided by jails within counties participating in the HCS. The survey will last approximately 15 minutes. You will be asked to complete this survey once a year for the next three years. About 200 key employees within participating jails will be asked to complete this survey. Before we begin, I would like to review a few items: Participation. Your participation in this survey is voluntary and you can stop participating at any time without penalty or loss of benefits to which you are otherwise entitled. If at any time you are uncomfortable with any question, you can choose not to answer. This study is for research purposes only, there is no direct benefit and your only alternative is to not participate. There is no cost to you, and you will not be paid for taking part in this survey. We will not share your name and contact information with anyone outside of the research team. The study Investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name. This means that absolute confidentiality cannot be guaranteed. We are conducting this survey once a year and would like to contact you again to participate in future surveys. Benefits and Risk. You will receive no direct benefits from participating in this study. However, your responses may help us learn more about opioid overdose deaths in your community and potential reduction strategies. There are no physical risks to participating in the study. You will not be asked to provide personal information other than basic demographics, and we will protect your confidentiality. There is a risk that someone could get access to the stored information. Despite the

hcs22_consent_phone

security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now. Reporting. As part of this study, we will write a report summarizing what we learned from these surveys. We will not use your name or any identifying information in the report. This report and study-related records may be shared with research staff at the HCS research sites, staff at the HCS Data Coordinating Center at RTIInternational, project staff at NIDA, and under certain circumstances, the Institutional Review Board (IRB).Future Research. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. After we remove all identifiers, we would like to securely store, use, and share these data for future research without additional informed consent.If you have questions, concerns or complaints about the study, please ask them now, or contact the study investigator. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact Advarra IRB. The toll-free number is 877-992-4724 and the email address is adviser@advarra.com. Please reference the following number when contacting the Study Participant Adviser: Pro00038088. Do you have any questions before we begin? (descriptive in matrix `hcs22_consent_phone`)

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [`hcs22_mode_survey`]='1'

KEY INFORMATION We are asking you to choose whether or not to volunteer for the HEALing Communities Study funded by the National Institute on Drug Abuse and conducted by four academic institutions: Boston Medical Center, Columbia University, University of Kentucky, and The Ohio State University. This study uses community engagement as a means to increase the use of evidence-based approaches with the goal of reducing opioid-related mortality by 40% over the course of the research study. We are asking you to participate because as a key employee within jails associated with communities

`hcs22_consent_web`

engaged in the HCS, you have information and opinions relevant to addressing the opioid epidemic. The details below may help you decide whether or not to participate. If you have questions, the contact information for the study investigator in charge of the study is provided above.

PARTICIPATION Participation in this survey should take approximately 15 minutes to complete and will involve about 200 other key jail employees. This survey is repeated once a year for the next three years to assess whether the breadth and utilization of these services change over time. Your participation is voluntary. You may refuse at any time without penalty or loss of benefits to which you are otherwise entitled. Your decision will not affect your current employment status, future advancement, or your relationship with the HEALing Communities Study team.

COMPENSATION You will not receive compensation for completing this survey.

BENEFITS & RISKS You will receive no direct benefits from participating in this study. However, your responses may help us to learn more about opioid overdose deaths in your community and potential reduction strategies. There are no physical risks to participating in the study. You will not be asked to provide personal information other than basic demographics, and we will protect your confidentiality. There is a risk that someone could get access to the stored information. Despite the security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. After we remove all identifiers, we would like to securely store, use, and share these data for future research without additional informed consent. There may be risks which are unforeseeable.

IF YOU DON'T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER CHOICES? There are no other choices except not to take part in the survey.

WHAT WILL IT COST YOU TO PARTICIPATE? There is no cost to you for participating in this study.

CAN YOU CHOOSE TO WITHDRAW FROM THE STUDY EARLY? If you decide to take part in the study, you still have the right to decide at any time that you no longer want to continue. No one will think badly of you or treat you differently if you decide not to take part in this study. If you choose to leave the study early, data collected until that point will remain in the study database and may not be removed. The study investigator or sponsor can stop your participation at any time without your consent for

the following reasons: If you fail to follow directions for participating in the study; If it is discovered that you do not meet the study requirements; If the study is canceled; or For administrative reasons. Any new important information that is discovered during the study that may influence your willingness to continue participation in the study will be given to you. You may refuse to participate, or you may withdraw from the study at any time, without penalty.

CONFIDENTIALITY We will not share your name and contact information with anyone outside of the research team. Your data will be assigned a unique, coded participant ID. Survey responses will be securely transmitted and stored at the HCS Data Coordinating Center at RTI International in North Carolina on a secure server and will contain personally identifiable information such as your name and email address. Your data will be combined with that of other participants and will only be reported in the aggregate. The study investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name.

THIS STUDY IS COVERED BY A CERTIFICATE OF CONFIDENTIALITY from the National Institutes of Health. The study investigators with this Certificate may not disclose or use information or documents that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information or documents protected by this Certificate cannot be disclosed to anyone else who is not connected with the study except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or neglect, harm to self or others, or communicable diseases), but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings; if you have consented to the disclosure; or if it is used for other scientific research, as allowed by federal regulations protecting research participants. The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the project that is needed for auditing or program evaluation by National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration, which are funding this project. You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this study.

WHOM TO CONTACT ABOUT THIS STUDY During the study, if you have questions, concerns, or complaints

about the study, please contact the Investigator at the telephone number listed on the first page of this consent document. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact: By mail: Study Participant Adviser Advarra IRB6940 Columbia Gateway Drive, Suite 110 Columbia, MD 21046 or call toll free: 877-992-4724 or by email: adviser@advarra.com Please reference the following number when contacting the Study Participant Adviser: Pro00038088. A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. CONSENT I have read and understand this informed consent information. I have had an opportunity to ask questions if needed, and all of my questions have been answered to my satisfaction. I voluntarily agree to participate in this study until I decide otherwise. I do not give up any of my legal rights by agreeing to this consent information. Once you have read this consent form, if you choose to participate and you are 18 years of age or older, click on I agree to begin the survey. You may print this page for your records. (descriptive)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='2'

I have read and understand the information in this informed consent document. I have had an opportunity to ask questions and all of my questions have been answered to my satisfaction. I am 18 years of age or older, and voluntarily agree to participate in this study until I decide otherwise. I do not give up any of my legal rights by signing and dating this consent document. I will receive a copy of this signed and dated consent document. (descriptive)

hcs22_consent_language_inperson

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='3'

Do I have your consent to participate? [if a verbal "yes" then continue] (descriptive)

hcs22_consent_language_phone

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_consent_phone_2]='1'

Once you have read this consent form, if you choose to participate and you are 18 years of age or older, click I agree to begin the study survey. You may print this page for your records. (descriptive)

hcs22_consent_language_web

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_mode_survey]='2'

3. Instrument: jail_survey

HCS Annual Jail Survey (descriptive)	hcs22_title
<p>Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0</p>	
<p>IMPORTANT DEFINITIONS This survey focuses on the following medications to treat opioid use disorder (OUD), as well as medications associated with the treatment of opioid withdrawal or overdose. Medications used to treat opioid use disorders: Buprenorphine: This is any partial agonist buprenorphine/buprenorphine-naloxone medication used for the treatment of opioid use disorders. Brand names include Suboxone®, Subutex®, Sublocade®, Zubsolv®, Bunavail®, Butrans®, Buprenex®, Probuphine®, and Belbuca®. Methadone: This is the full agonist medication used for the treatment of opioid use disorders. Brand names include Methadose®, Dolophine®, Diskets®, and Methadone Intenso!®. Naltrexone: This is a full antagonist medication used for the treatment of opioid use disorders. Brand names include: Vivitrol®, ReVia®, Adepend®, Depade®, Nalorex®, and Trexan®</p> <p>Classes or medications associated with the treatment of opioid withdrawal or overdose:</p> <p>Benzodiazepines: This class of drugs is often used to mitigate withdrawal symptoms after discontinuation of opioids in adults. Examples include: Chlordizepoxide, Clonazepam®, and Librium. Clonidine: This is used for multiple conditions, including mitigation of withdrawal symptoms after abrupt discontinuation of opioids in adults. Lofexidine: This is used to mitigate withdrawal symptoms after abrupt discontinuation of opioids in adults. Brand names include: Lucemyra®</p> <p>Naloxone: This medication is an opioid antagonist. It is used to rapidly reverse the effects of opiates and is available in both injectable and inhaled formulations. Brand names include: Narcan®, and EVZIO® Some of these medications may also treat alcohol withdrawal and alcohol use disorders (e.g., Chlordiazepoxide, Librium, naltrexone); however, for the purpose of this survey we are asking about their use as medications for treatment of opioid use disorders (OUD). (descriptive)</p>	screen1
<p>Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0</p>	

SAMPLED TIMEFRAME The purpose of this survey is to capture the services provided during a 12-month time period. The 12-month reporting period will be from January 1, 2019 to December 31, 2019. Throughout the survey, when questions ask about "during the past 12 months," please use this 12-month timeframe described above. (descriptive) time_1

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

INSTRUCTIONS FOR INDIVIDUAL ITEMS When exact numeric answers are not available, please indicate whether the response provided is estimated, not accessible, or not collected. (descriptive) screen3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Profile of People Detained in the Jail To get a picture of the profile of people detained in the jail, these questions are about people who were **DETAINED** in the jail in the past 12 months. When answering, please **INCLUDE** - Jails and other confinement facilities-including detention centers -intended for adults but sometimes holding juveniles, that are either privately owned and operated or administered by two or more governments (or a board composed of representatives from two or more governments). Temporary holding or lockup facilities if they are part of your combined function. Detainees held for other jurisdictions, including federal authorities, state prison authorities, American Indian or Alaska Native tribal governments, and other local jail jurisdictions. **EXCLUDE** - Services for individuals held by other jurisdictions. Services for individuals under community corrections or supervision who are **NOT** detained, including electronic monitoring, probation, parole, or diversion. Facilities that are exclusively used as temporary holding or lockup facilities, where detainees are generally held for less than 72 hours and not held beyond arraignment. (descriptive) screen4

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

hcs22_state (descriptive)

lbl_hcs22_state

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

hcs22_role (descriptive)

lbl_hcs22_role

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b1b_1 (descriptive)

lbl_b1b_1

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

c1a (descriptive)

lbl_c1a

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b2aa (descriptive)

lbl_b2aa

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b2aaa (descriptive)

lbl_b2aaa

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [b2aa] = '1' or [b2aa] = '2'

c1a1 (descriptive)

lbl_c1a1

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b2ba (descriptive)	lbl_b2ba
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0	

b2baa (descriptive)	lbl_b2baa
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [b2ba] = '1' or [b2ba] = '2'	

c1a2_u (descriptive)	lbl_c1a2_u
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [b1b_1]='2' or [b1b_1]='3'	

b2ca (descriptive)	lbl_b2ca
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [b1b_1]='2' or [b1b_1]='3'	

b2caa (descriptive)	lbl_b2caa
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [b2ca] = '1' or [b2ca] = '2'	

c1c_u (descriptive)	lbl_c1c_u
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0	

b2da (descriptive)	lbl_b2da
---------------------------	-----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b2daa (descriptive)	lbl_b2daa
----------------------------	------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [b2daa] = '1' or [b2daa] = '2'

b3 (descriptive)	lbl_b3
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b4 (descriptive)	lbl_b4
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

d1 (descriptive)	lbl_d1
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

d1a1 (descriptive)	lbl_d1a1
---------------------------	-----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1a1] <> '0'

d1a99_text (descriptive)	lbl_d1a99_text
---------------------------------	-----------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1]<>'0'

d1b1 (descriptive)	lbl_d1b1
---------------------------	-----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1]<>'0'

d1b99_text (descriptive)	lbl_d1b99_text
---------------------------------	-----------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1]<>'0'

e1 (descriptive)	lbl_e1
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

e1a1 (descriptive)	lbl_e1a1
---------------------------	-----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e1]<>'0'

e1a99_text (descriptive)	lbl_e1a99_text
---------------------------------	-----------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e1]<>'0'

e2 (descriptive)	lbl_e2
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

e2a1 (descriptive) **lbl_e2a1**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e2]<>'0'

e2a99_text (descriptive) **lbl_e2a99_text**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e2]<>'0'

f1 (descriptive) **lbl_f1**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

f2 (descriptive) **lbl_f2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0'

f2a2 (descriptive) **lbl_f2a2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: ([b1b_1]='2' or [b1b_1]='3') and [f1]<>'0' and [f2]<>'0'

f2b2 (descriptive) **lbl_f2b2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Branching logic: [f1]<>'0' and [f2]<>'0'

f2b4 (descriptive)

lbl_f2b4

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f2]<>'0'

f2e (descriptive)

lbl_f2e

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f2]<>'0'

e2ba (descriptive)

lbl_e2ba

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f2]<>'0'

e2baa (descriptive)

lbl_e2baa

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e2ba] = '1'

e3 (descriptive)

lbl_e3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0'

e3a (descriptive)

lbl_e3a

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [e3]<>'0'

e3aa (descriptive)	lbl_e3aa
---------------------------	-----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [e3]<>'0'

e3aaa (descriptive)	lbl_e3aaa
----------------------------	------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e3aa] = '1'

f5 (descriptive)	lbl_f5
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0'

f5a2 (descriptive)	lbl_f5a2
---------------------------	-----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: ([b1b_1]='2' or [b1b_1]='3') and [f1]<>'0' and [f5]<>'0' and [f5] <> "

f5b2 (descriptive)	lbl_f5b2
---------------------------	-----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f5]<>'0' and [f5] <> "

f5b4 (descriptive)	lbl_f5b4
---------------------------	-----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f5]<>'0' and [f5] <> "

f5e (descriptive)**lbl_f5e**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f5]<>'0' and [f5] <> "

e4ba (descriptive)**lbl_e4ba**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f5]<>'0' and [f5] <> "

e4baa (descriptive)**lbl_e4baa**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e4ba] = '1'

f8 (descriptive)**lbl_f8**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0'

f8b2 (descriptive)**lbl_f8b2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f8]<>'0' and [f8] <> "

f8b3 (descriptive)**lbl_f8b3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f8]<>'0' and [f8] <> "

f8e (descriptive)**lbl_f8e**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f8]<>'0' and [f8] <> "

e5ba (descriptive)**lbl_e5ba**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1]<>'0' and [f8]<>'0' and [f8] <> "

e5baa (descriptive)**lbl_e5baa**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e5ba] = '1'

j2 (descriptive)**lbl_j2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

j4 (descriptive)**lbl_j4**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

j5 (descriptive)**lbl_j5**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

j6a (descriptive)**lbl_j6a**

Field type: descriptive

Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [j5]<>'0' and [j5] <> "

f3aa (descriptive)**lbl_f3aa**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [j5]<>'0' and [j5] <> "

f3aaa (descriptive)**lbl_f3aaa**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f3aa] ='1'

k1a (descriptive)**lbl_k1a**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

k1z_text (descriptive)**lbl_k1z_text**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

k2a (descriptive)**lbl_k2a**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

k2z_text (descriptive)**lbl_k2z_text**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

n7 (descriptive)	lbl_n7
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state]='3'	
Recent bail reform legislation in New York ended the use of cash bail for most misdemeanors and Class E felonies. This reform led to the release of many people in county jails who were no longer eligible to be held on bail as well as other impacts on arrests and arraignment. The next questions are about how the most recent bail reform legislation impacted your jail, including population census. Please provide us with your best estimate if possible. (descriptive)	bailintro
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state]='3'	
n1 (descriptive)	lbl_n1
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state]='3'	
n2 (descriptive)	lbl_n2
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state]='3' AND [n1]<>'0' AND [n2]=''	
n3 (descriptive)	lbl_n3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state]='3' AND [n1]<>'0'	

n4 (descriptive)	lbl_n4
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

n5 (descriptive)	lbl_n5
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state]='3' AND [n1]<>'0'

n5a (descriptive)	lbl_n5a
--------------------------	----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state]='3' AND [n5]='0' and [n1]<>'0'

n5b (descriptive)	lbl_n5b
--------------------------	----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state]='3' AND [n5]='1' and [n1]<>'0'

Bail reforms were expected to change the number and types of persons being held in jail. (descriptive)	n6_desc
---	----------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state]='3'

n6 (descriptive)	lbl_n6
-------------------------	---------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state]='3'

n6a (descriptive)

lbl_n6a

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state]='3' and [n6]='1'

n6b (descriptive)

lbl_n6b

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state]='3' and [n6]='2'

That was the last question. Thank you for your time.

This survey contains multiple items adapted with permission from Scott, C.K, & Dennis, M.L. (2019). Justice Community Opioid Innovation Network (JCOIN): Jail Interview Protocol. Chicago, IL: Chestnut Health Systems. (descriptive)

endsurvey

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

4. Instrument: informed_consent_year_2

**CONSENT TO PARTICIPATE IN A RESEARCH
STUDY**HCS Annual Jail Survey (descriptive)

ic_hd_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_mode_survey]='2' or [hcs22_mode_survey]='3'

**CONSENT TO PARTICIPATE IN A RESEARCH
STUDY**HCS Annual Jail Survey Use this verbal
consent for data collection if the participant is not
present in-person and the survey is conducted by
phone. (descriptive)

ic_hd_phone_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_mode_survey]='1'

**Sponsor / Study Title: The National Institute on
Drug Abuse / "The HEALing Communities Study
(HCS)" Principal Investigator: Bridget Freisthler,
Ph.D. Telephone: (614) 293-4041(614) 293-8000
(24 Hours) Address: The Ohio State University-
Pomerene Hall1760 Neil Avenue Suite
380Columbus, OH 43210 (descriptive)**

ic_hd_contact_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_mode_survey]='2' or [hcs22_mode_survey]='3'

KEY INFORMATION We are asking you to choose
whether or not to participate in the HEALing
Communities Study funded by the National
Institute on Drug Abuse and conducted by four
academic institutions: Boston Medical Center,
Columbia University, University of Kentucky, and
The Ohio State University. This study uses
community engagement as a means to increase
the use of evidence-based approaches with the
goal of reducing opioid-related mortality by 40%
over the course of the research study. We are
asking you to participate because as a key
employee within jails associated with communities
engaged in the HCS, you have information and
opinions relevant to addressing the opioid

hcs22_consent_inperson_y2

epidemic. This page gives you key information to help you decide whether to participate. We have included detailed information following this page. Ask the research study team questions. If you have questions later, the contact information for the research study investigator in charge of the study is provided above. **WHAT IS THE STUDY ABOUT AND HOW LONG WILL IT LAST?** By doing this study, we hope to learn how community coalitions can most effectively respond to the opioid epidemic and reduce opioid-related deaths. The primary study goal is to reduce the number of opioid overdose deaths by at least 40% in 67 selected communities over the next three years by working with community coalitions. Your participation in this research survey should take approximately 15 minutes and the survey is repeated once a year for the next three years. We anticipate that 200 other key jail employees will participate in this survey. **WHAT ARE KEY REASONS YOU MIGHT CHOOSE TO PARTICIPATE IN THIS STUDY?** By choosing to participate in this study, you may help to reduce the negative impacts of the opioid epidemic for individuals, families, and communities. For a complete description of benefits, refer to the Detailed Consent. **WHAT ARE KEY REASONS YOU MIGHT CHOOSE NOT TO PARTICIPATE IN THIS STUDY?** There are no foreseeable physical risks involved with this study. For a description of the potential risks, refer to the Detailed Consent. **DO YOU HAVE TO TAKE PART IN THE STUDY?** If you decide to take part in this study, it should be because you really want to participate. You will not lose any services, benefits or rights you would normally have if you choose not to participate. Your decision will not affect your relationship with your employer or the HEALing Communities Study research team. **WHOM TO CONTACT ABOUT THIS STUDY** During the study, if you have questions, concerns, or complaints about the study, please contact the Investigator at the telephone number listed on the first page of this consent document. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact: By mail: Study Participant Adviser Advarra IRB6940 Columbia Gateway Drive, Suite 110 Columbia, MD 21046 or call toll free: 877-992-4724 or by email: adviser@advarra.com Please reference the following number when contacting the Study Participant Adviser: Pro00038088. **DETAILED CONSENT: WHAT WILL YOU BE ASKED TO DO AND WHAT IS THE TOTAL AMOUNT OF TIME INVOLVED?** A number of different research study activities will be involved during different phases of the study. If you agree to be part of the study,

you will be asked to take part in a survey to ask you about the opioid-related services provided by jails in communities participating in HCS. The survey will take approximately 15 minutes to complete and will be repeated once a year for the next three years. Even if you agree to participate in the research study now, you may at any time decline to participate. Doing so will not affect your current work status, future advancement, or your relationship with the HEALing Communities Study research team.

WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? No physical risks are involved in this study. The risk of a breach in confidentiality of your study data is minimized by the procedures in place to protect your privacy. You will not be asked to provide personal information other than basic demographic information. Although we would like you to answer all the survey questions asked of you, you may choose not to answer questions without any negative consequences. There may be risks which are currently unforeseeable.

WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY? You will receive no direct benefits from participating in this research study. However, your participation could assist your community in examining procedures and improving services for individuals with opioid use disorder or at risk of opioid overdose. Your participation may also help your community by enhancing the process and communication among organizations involved.

IF YOU DON'T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER CHOICES? If you do not want to be in the study, there are no other choices except to not take part in the study.

WHAT WILL IT COST YOU TO PARTICIPATE? There is no cost to you to participate in the study.

WHO WILL SEE THE INFORMATION THAT YOU GIVE? We will make every effort to keep private all research study records that identify you to the extent allowed by law. Study data will be collected, managed, and analyzed by the four research sites and RTI International, the Data Coordinating Center located in North Carolina. Any data that are stored electronically will reside in a password-protected database on a secure server. Research records will be deidentified and stored using a secure participant identification number. These identification numbers will be used for combining data from various surveys and interviews, which will be important for analyzing the data. Your information will be combined with information from other people taking part in the study. The study investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name. This means that absolute confidentiality cannot be guaranteed. We will

publish the results of this study only in the aggregate, and you will not be identified directly or indirectly in study reports and presentations.

THIS RESEARCH STUDY IS COVERED BY A CERTIFICATE OF CONFIDENTIALITY from the National Institutes of Health. Study investigators with this Certificate may not disclose or use information or documents that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information or documents protected by this Certificate cannot be disclosed to anyone else who is not connected with the research study except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or neglect, harm to self or others, or communicable diseases), but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings; if you have consented to the disclosure; or if it is used for other scientific research, as allowed by federal regulations protecting research participants. The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the study that is needed for auditing or program evaluation by National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration, which are funding this study. You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this research study.

CAN YOU CHOOSE TO WITHDRAW FROM THE STUDY EARLY? You can choose to leave the study at any time. If you decide to take part in the study, you still have the right to decide at any time that you no longer want to continue. No one will think badly of you or treat you differently if you decide not to take part in this study. If you choose to leave the study early, data collected until that point will remain in the study database and may not be removed. The study investigator or sponsor can stop your participation at any time without your consent for the following reasons: If you fail to follow directions for participating in the study; If it is discovered that you do not meet the study requirements; If the study is canceled; or For administrative reasons. Any new important information that is discovered during the study that may influence your willingness to continue participation in the study will be given to you. You may refuse to participate, or you may withdraw from the study at any time, without penalty.

WILL YOU RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY? You will not receive compensation for completing the survey.

HOW

WILL YOUR PRIVACY AND CONFIDENTIALITY BE PROTECTED? We will take careful steps to keep your information confidential. All identifiable information (for example, your name) will be removed from the information collected in this study. We will make every effort to prevent anyone who is not on the research team from knowing that you gave us information, or what that information is. For example, your name will be kept separate from the information you give, and these two things will be stored in different places under lock and key. We will label your information with a code and will store the key separately from the master code list. Only select study staff will have access to the list that links the code to you. All research data will be kept in locked file cabinets. Computer files will be retained, and all electronic data will be password protected, stored on secure servers, and accessible only to the researchers on this study.

WILL YOUR INFORMATION BE STORED AND USED FOR FUTURE RESEARCH? All identifiable information (for example, your name, employer, and contact information) will be removed from the information collected for this study. After we remove all identifiers, the information you provide during the study may be used for analysis or shared with other researchers without your additional informed consent. The deidentified information will be stored on secure servers at the research sites and the data coordinating center at RTI International during the study. We plan to store and share deidentified data from surveys and interviews for future research. Data collected or transmitted under this study will be maintained for at least 3 years. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. Researchers can use the stored information to research additional scientific questions. There is a risk that someone could get access to the stored information. Despite the security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now.

WHAT ELSE DO YOU NEED TO KNOW? If you agree to take part in this study, you will be one of about 200 key jail employees to do so. The National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration are providing financial support for this study. A description of this clinical trial will be available on <http://www.clinicaltrials.gov/> as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results.

**You can search this Web site at any time.
(descriptive)**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='3'

Hello. My name is [name] and I work for the HEALing Communities Study (HCS) in your state. We are working with the National Institute on Drug Abuse (NIDA) and research sites in three other participating states to conduct the HEALing Communities Study. This study uses community engagement as a means to increase the use of evidence-based approaches with the goal of reducing opioid-related mortality by 40% over the course of the research study. We are conducting surveys to assess the provision of opioid use disorder related services provided by jails within counties participating in the HCS. The survey will last approximately 15 minutes. You will be asked to complete this survey once a year for the next three years. About 200 key employees within participating jails will be asked to complete this survey. Before we begin, I would like to review a few items: Participation. Your participation in this survey is voluntary and you can stop participating at any time without penalty or loss of benefits to which you are otherwise entitled. If at any time you are uncomfortable with any question, you can choose not to answer. This study is for research purposes only, there is no direct benefit and your only alternative is to not participate. There is no cost to you, and you will not be paid for taking part in this survey. We will not share your name and contact information with anyone outside of the research team. The study Investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name. This means that absolute confidentiality cannot be guaranteed. We are conducting this survey once a year and would like to contact you again to participate in future surveys. Benefits and Risk. You will receive no direct benefits from participating in this study. However, your responses may help us learn more about opioid overdose deaths in your community and potential reduction strategies. There are no physical risks to participating in the study. You will not be asked to provide personal information other than basic demographics, and we will protect your confidentiality. There is a risk that someone could get access to the stored information. Despite the

hcs22_consent_phone_y2

security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now. Reporting. As part of this study, we will write a report summarizing what we learned from these surveys. We will not use your name or any identifying information in the report. This report and study-related records may be shared with research staff at the HCS research sites, staff at the HCS Data Coordinating Center at RTI International, project staff at NIDA, and under certain circumstances, the Institutional Review Board (IRB). Future Research. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. After we remove all identifiers, we would like to securely store, use, and share these data for future research without additional informed consent. If you have questions, concerns or complaints about the study, please ask them now, or contact the study investigator. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact Advarra IRB. The toll-free number is 877-992-4724 and the email address is adviser@advarra.com. Please reference the following number when contacting the Study Participant Adviser: Pro00038088. Do you have any questions before we begin? (descriptive)

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: `[hcs22_mode_survey]='1'`

KEY INFORMATION We are asking you to choose whether or not to volunteer for the HEALing Communities Study funded by the National Institute on Drug Abuse and conducted by four academic institutions: Boston Medical Center, Columbia University, University of Kentucky, and The Ohio State University. This study uses community engagement as a means to increase the use of evidence-based approaches with the goal of reducing opioid-related mortality by 40% over the course of the research study. We are asking you to participate because as a key employee within jails associated with communities engaged in the HCS, you have information and

`hcs22_consent_web_y2`

opinions relevant to addressing the opioid epidemic. The details below may help you decide whether or not to participate. If you have questions, the contact information for the study investigator in charge of the study is provided above. **PARTICIPATION** Participation in this survey should take approximately 15 minutes to complete and will involve about 200 other key jail employees. This survey will be repeated next year to assess whether the breadth and utilization of these services change over time. Your participation is voluntary. You may refuse at any time without penalty or loss of benefits to which you are otherwise entitled. Your decision will not affect your current employment status, future advancement, or your relationship with the HEALing Communities Study team.

COMPENSATION You will not receive compensation for completing this survey.

BENEFITS & RISKS You will receive no direct benefits from participating in this study. However, your responses may help us to learn more about opioid overdose deaths in your community and potential reduction strategies. There are no physical risks to participating in the study. You will not be asked to provide personal information other than basic demographics, and we will protect your confidentiality. There is a risk that someone could get access to the stored information. Despite the security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. After we remove all identifiers, we would like to securely store, use, and share these data for future research without additional informed consent. There may be risks which are unforeseeable. **IF YOU DON'T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER CHOICES?** There are no other choices except not to take part in the survey. **WHAT WILL IT COST YOU TO PARTICIPATE?** There is no cost to you for participating in this study. **CAN YOU CHOOSE TO WITHDRAW FROM THE STUDY EARLY?** If you decide to take part in the study, you still have the right to decide at any time that you no longer want to continue. No one will think badly of you or treat you differently if you decide not to take part in this study. If you choose to leave the study early, data collected until that point will remain in the study database and may not be removed. The study investigator or sponsor can stop your participation at any time without your consent for the following reasons: If you fail to follow

directions for participating in the study; If it is discovered that you do not meet the study requirements; If the study is canceled; or For administrative reasons. Any new important information that is discovered during the study that may influence your willingness to continue participation in the study will be given to you. You may refuse to participate, or you may withdraw from the study at any time, without penalty.

CONFIDENTIALITY We will not share your name and contact information with anyone outside of the research team. Your data will be assigned a unique, coded participant ID. Survey responses will be securely transmitted and stored at the HCS Data Coordinating Center at RTI International in North Carolina on a secure server and will contain personally identifiable information such as your name and email address. Your data will be combined with that of other participants and will only be reported in the aggregate. The study investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name. **THIS STUDY IS COVERED BY A CERTIFICATE OF CONFIDENTIALITY** from the National Institutes of Health. The study investigators with this Certificate may not disclose or use information or documents that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information or documents protected by this Certificate cannot be disclosed to anyone else who is not connected with the study except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or neglect, harm to self or others, or communicable diseases), but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings; if you have consented to the disclosure; or if it is used for other scientific research, as allowed by federal regulations protecting research participants. The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the project that is needed for auditing or program evaluation by National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration, which are funding this project. You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this study. **WHOM TO CONTACT ABOUT THIS STUDY** During the study, if you have questions, concerns, or complaints about the study, please contact the Investigator at

the telephone number listed on the first page of this consent document. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact: By mail: Study Participant Adviser Advarra IRB6940 Columbia Gateway Drive, Suite 110 Columbia, MD 21046 or call toll free: 877-992-4724 or by email: adviser@advarra.com Please reference the following number when contacting the Study Participant Adviser: Pro00038088. A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. CONSENT I have read and understand this informed consent information. I have had an opportunity to ask questions if needed, and all of my questions have been answered to my satisfaction. I voluntarily agree to participate in this study until I decide otherwise. I do not give up any of my legal rights by agreeing to this consent information. Once you have read this consent form, if you choose to participate and you are 18 years of age or older, click on I agree to begin the survey. You may print this page for your records. (descriptive)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='2'

I have read and understand the information in this informed consent document. I have had an opportunity to ask questions and all of my questions have been answered to my satisfaction. I am 18 years of age or older, and voluntarily agree to participate in this study until I decide otherwise. I do not give up any of my legal rights by signing and dating this consent document. I will receive a copy of this signed and dated consent document. (descriptive)

hcs22_consent_language_inperson_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='3'

Do I have your consent to participate? [if a verbal

hcs22_consent_language_phone_y2

"yes" then continue] (descriptive)

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_consent_phone_2_y2]='1'

Once you have read this consent form, if you choose to participate and you are 18 years of age or older, click I agree to begin the study survey. You may print this page for your records. (descriptive)

hcs22_consent_language_web_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_mode_survey]='2'

5. Instrument: jail_survey_year_2

HCS Annual Jail Survey (descriptive)

hcs22_title_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

IMPORTANT DEFINITIONS This survey focuses on the following medications to treat opioid use disorder (OUD), as well as medications associated with the treatment of opioid withdrawal or overdose. Medications used to treat opioid use disorders: **Buprenorphine:** This is any partial agonist buprenorphine/buprenorphine-naloxone medication used for the treatment of opioid use disorders. Brand names include Suboxone®, Subutex®, Sublocade®, Zubsolv®, Bunavail®, Butrans®, Buprenex®, Probuphine®, and Belbuca®. **Methadone:** This is the full agonist medication used for the treatment of opioid use disorders. Brand names include Methadose®, Dolophine®, Diskets®, and Methadone Intenso!®. **Naltrexone:** This is a full antagonist medication used for the treatment of opioid use disorders. Brand names include: Vivitrol®, ReVia®, Adepend®, Depade®, Nalorex®, and Trexan® **Classes or medications associated with the treatment of opioid withdrawal or overdose:** **Benzodiazepines:** This class of drugs is often used to mitigate withdrawal symptoms after discontinuation of opioids in adults. Examples include: Chlordiazepoxide, Clonazepam®, and Librium. **Clonidine:** This is used for multiple conditions, including mitigation of withdrawal symptoms after abrupt discontinuation of opioids in adults. **Lofexidine:** This is used to mitigate withdrawal symptoms after abrupt discontinuation of opioids in adults. Brand names include: Lucemyra® **Naloxone:** This medication is an opioid antagonist. It is used to rapidly reverse the effects of opiates and is available in both injectable and inhaled formulations. Brand names include: Narcan®, and EVZIO® Some of these medications may also treat alcohol withdrawal and alcohol use disorders (e.g., Chlordiazepoxide, Librium, naltrexone); however, for the purpose of this survey we are asking about their use as medications for treatment of opioid use disorders (OUD). (descriptive)

screen1_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

SAMPLED TIMEFRAME The purpose of this survey is to capture the services provided during a 12-month time period. The 12-month reporting period will be from July 1, 2020 to June 30, 2021. (descriptive) time_1_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Profile of People Detained in the Jail To get a picture of the profile of people detained in the jail, these questions are about people who were **DETAINED** in the jail between July 1, 2020 and June 30, 2021. By detained, we mean booked into the jail. When answering, please **INCLUDE** - Jails and other confinement facilities-including detention centers -intended for adults but sometimes holding juveniles, that are either privately owned and operated or administered by two or more governments (or a board composed of representatives from two or more governments). Temporary holding or lockup facilities if they are part of your combined function. Detainees held for other jurisdictions, including federal authorities, state prison authorities, American Indian or Alaska Native tribal governments, and other local jail jurisdictions. **EXCLUDE** - Services for individuals held by other jurisdictions. Services for individuals under community corrections or supervision who are NOT detained, including electronic monitoring, probation, parole, or diversion. Facilities that are exclusively used as temporary holding or lockup facilities, where detainees are generally held for less than 72 hours and not held beyond arraignment. (descriptive) screen4_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

hcs22_state (descriptive) **lbl_hcs22_state_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

hcs22_role (descriptive) **lbl_hcs22_role_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b1b_1 (descriptive) **lbl_b1b_1_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

c1a (descriptive) **lbl_c1a_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

c1a1 (descriptive) **lbl_c1a1_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

c1a2_u (descriptive) **lbl_c1a2_u_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [b1b_1_y2]='2' or [b1b_1_y2]='3'

c1c_u (descriptive) **lbl_c1c_u_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b3 (descriptive) **lbl_b3_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

b4 (descriptive)	lbl_b4_y2
-------------------------	------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

ca1 (descriptive)	lbl_ca1_y2
--------------------------	-------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

d1 (descriptive)	lbl_d1_y2
-------------------------	------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

d1a1 (descriptive)	lbl_d1a1_y2
---------------------------	--------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1_y2]<>'0'

d1a99_text (descriptive)	lbl_d1a99_text_y2
---------------------------------	--------------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1_y2]<>'0'

d1b1 (descriptive)	lbl_d1b1_y2
---------------------------	--------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1_y2]<>'0'

d1b99_text (descriptive)	lbl_d1b99_text_y2
---------------------------------	--------------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1_y2]<>'0'

e1 (descriptive)	lbl_e1_y2
-------------------------	------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

e1a1 (descriptive)	lbl_e1a1_y2
---------------------------	--------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e1_y2]<>'0'

Does the protocol include any of the following tools to screen for opioid withdrawal? (descriptive in matrix e1a1_text)	e1a1_text
--	------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e1_y2]<>'0'

e1a99_text (descriptive)	lbl_e1a99_text_y2
---------------------------------	--------------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e1_y2]<>'0'

e2 (descriptive)	lbl_e2_y2
-------------------------	------------------

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

e2a1 (descriptive)**lbl_e2a1_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e2_y2]<>'0'

e2a99_text (descriptive)**lbl_e2a99_text_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e2_y2]<>'0'

f1 (descriptive)**lbl_f1_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

f2 (descriptive)**lbl_f2_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0'

f2a2 (descriptive)**lbl_f2a2_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: ([b1b_1_y2]='2' or [b1b_1_y2]='3') and [f1_y2]<>'0' and [f2_y2]<>'0'

f2b2 (descriptive)**lbl_f2b2_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0' and [f2_y2]<>'0'

f2b4 (descriptive)**lbl_f2b4_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0' and [f2_y2]<>'0'

f2b1 (descriptive)**lbl_f2b1_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0' and [f2_y2]<>'0'

f2e (descriptive)**lbl_f2e_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0' and [f2_y2]<>'0'

e3 (descriptive)**lbl_e3_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0'

e3a (descriptive)**lbl_e3a_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0' and [e3_y2]<>'0'

f5 (descriptive)**lbl_f5_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0'

f5a2 (descriptive)**lbl_f5a2_y2**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: ([b1b_1_y2]='2' or [b1b_1_y2]='3') and [f1_y2]<>'0' and [f5_y2]<>'0' and [f5_y2] <> "

f5b2 (descriptive)

lbl_f5b2_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [f1_y2]<>'0' and [f5_y2]<>'0' and [f5_y2] <> "

f5b4 (descriptive)

lbl_f5b4_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [f1_y2]<>'0' and [f5_y2]<>'0' and [f5_y2] <> "

f5e (descriptive)

lbl_f5e_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [f1_y2]<>'0' and [f5_y2]<>'0' and [f5_y2] <> "

f8 (descriptive)

lbl_f8_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [f1_y2]<>'0'

f8b2 (descriptive)

lbl_f8b2_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [f1_y2]<>'0' and [f8_y2]<>'0' and [f8_y2] <> "

f8b3 (descriptive)

lbl_f8b3_y2

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0
Branching logic: [f1_y2]<>'0' and [f8_y2]<>'0' and [f8_y2] <> "

f8e (descriptive) **lbl_f8e_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2]<>'0' and [f8_y2]<>'0' and [f8_y2] <> "

j2 (descriptive) **lbl_j2_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

j4 (descriptive) **lbl_j4_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

j5 (descriptive) **lbl_j5_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

j6a (descriptive) **lbl_j6a_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [j5_y2]<>'0' and [j5_y2] <> "

k1a (descriptive) **lbl_k1a_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

k1z_text (descriptive)**lbl_k1z_text_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

k2a (descriptive)**lbl_k2a_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

k2z_text (descriptive)**lbl_k2z_text_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

COVIDINTRO (descriptive in matrix lbl_covidintro) lbl_covidintro

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

The COVID-19 pandemic required a major crisis response and policy change in order to reduce the risks of transmission and to promote health of those who were detained. This crisis response led to the release of many people in county jails. The next questions are about how the COVID-19 pandemic policy changes impacted your jail, including population census. Please provide us with your best estimate if possible. (descriptive in matrix covidintro)

covidintro

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

O1 (descriptive)**lbl_o1_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

O2 (descriptive) **lbl_o2_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o1_y2] = '1'

O3 (descriptive) **lbl_o3_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o1_y2] <> '0'

O4 (descriptive) **lbl_o4_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o1_y2] <> '0' and [f1_y2] = '1'

O5 (descriptive) **lbl_o5_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y2] = '1'

O5-2 (descriptive) **lbl_o5_2_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o1_y2] <> '0'

O5a (descriptive) **lbl_o5a_y2**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o5_2_y2] = '0' and [o1_y2] <> '0'

O5b (descriptive)

lbl_o5b_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o5_2_y2] = '1' and [o1_y2] <> '0'

O6 (descriptive)

lbl_o6_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

O6a (descriptive)

lbl_o6a_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o6_y2] = '1'

O6b (descriptive)

lbl_o6b_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o6_y2] = '2'

n7 (descriptive)

lbl_n7_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y2]='3'

Recent bail reform legislation in New York ended the use of cash bail for most misdemeanors and Class E felonies. This reform led to the release of many people in county jails who were no longer eligible to be held on bail as well as other impacts on arrests and arraignment. The next questions are about how the most recent bail reform legislation impacted your jail, including population census. Please provide us with your best estimate

bailintro_y2

if possible. (descriptive)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y2]='3'

n1 (descriptive) lbl_n1_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y2]='3'

n2 (descriptive) lbl_n2_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y2]='3' AND [n1_y2]<>'0' AND [n2_y2]=''

n3 (descriptive) lbl_n3_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y2]='3' AND [n1_y2]<>'0'

n4 (descriptive) lbl_n4_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y2]='3' AND [n1_y2]<>'0'

n5 (descriptive) lbl_n5_y2

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y2]='3' AND [n1_y2]<>'0'

n5a (descriptive)**lbl_n5a_y2**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_state_y2]='3' AND [n5_y2]='0' and [n1_y2]<>'0'

n5b (descriptive)**lbl_n5b_y2**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_state_y2]='3' AND [n5_y2]='1' and [n1_y2]<>'0'

**Bail reforms were expected to change the number
and types of persons being held in jail.
(descriptive)****n6_desc_y2**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_state_y2]='3'

n6 (descriptive)**lbl_n6_y2**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_state_y2]='3'

n6a (descriptive)**lbl_n6a_y2**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_state_y2]='3' and [n6_y2]='1'

n6b (descriptive)**lbl_n6b_y2**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [hcs22_state_y2]='3' and [n6_y2]='2'

That was the last question. Thank you for your time.

This survey contains multiple items adapted with permission from Scott, C.K, & Dennis, M.L. (2019). **endsurvey_y2**
Justice Community Opioid Innovation Network
(JCOIN): Jail Interview Protocol. Chicago, IL:
Chestnut Health Systems. (descriptive)

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

6. Instrument: informed_consent_year_3

Version # (text)	ic_version_y3
Field type: text Observations with this value left blank: 1 Number of unique values: 1	
CONSENT TO PARTICIPATE IN A RESEARCH STUDYHCS Annual Jail Survey (descriptive)	ic_hd_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_mode_survey]='2' or [hcs22_mode_survey]='3'	
CONSENT TO PARTICIPATE IN A RESEARCH STUDYHCS Annual Jail Survey Use this verbal consent for data collection if the participant is not present in-person and the survey is conducted by phone. (descriptive)	ic_hd_phone_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_mode_survey]='1'	
Sponsor / Study Title: The National Institute on Drug Abuse / "The HEALing Communities Study (HCS)" Principal Investigator: Bridget Freisthler, Ph.D. Telephone: (614) 293-4041(614) 293-8000 (24 Hours) Address: The Ohio State University-Pomerene Hall1760 Neil Avenue Suite 380Columbus, OH 43210 (descriptive)	ic_hd_contact_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_mode_survey]='2' or [hcs22_mode_survey]='3'	
KEY INFORMATION We are asking you to choose whether or not to participate in the HEALing Communities Study funded by the National Institute on Drug Abuse and conducted by four academic institutions: Boston Medical Center, Columbia University, University of Kentucky, and	hcs22_consent_inperson_y3

The Ohio State University. This study uses community engagement as a means to increase the use of evidence-based approaches with the goal of reducing opioid-related mortality by 40% over the course of the research study. We are asking you to participate because as a key employee within jails associated with communities engaged in the HCS, you have information and opinions relevant to addressing the opioid epidemic. This page gives you key information to help you decide whether to participate. We have included detailed information following this page. Ask the research study team questions. If you have questions later, the contact information for the research study investigator in charge of the study is provided above. **WHAT IS THE STUDY ABOUT AND HOW LONG WILL IT LAST?** By doing this study, we hope to learn how community coalitions can most effectively respond to the opioid epidemic and reduce opioid-related deaths. The primary study goal is to reduce the number of opioid overdose deaths by at least 40% in 67 selected communities over the next three years by working with community coalitions. Your participation in this research survey should take approximately 15 minutes. We anticipate that 200 other key jail employees will participate in this survey. **WHAT ARE KEY REASONS YOU MIGHT CHOOSE TO PARTICIPATE IN THIS STUDY?** By choosing to participate in this study, you may help to reduce the negative impacts of the opioid epidemic for individuals, families, and communities. For a complete description of benefits, refer to the Detailed Consent. **WHAT ARE KEY REASONS YOU MIGHT CHOOSE NOT TO PARTICIPATE IN THIS STUDY?** There are no foreseeable physical risks involved with this study. For a description of the potential risks, refer to the Detailed Consent. **DO YOU HAVE TO TAKE PART IN THE STUDY?** If you decide to take part in this study, it should be because you really want to participate. You will not lose any services, benefits or rights you would normally have if you choose not to participate. Your decision will not affect your relationship with your employer or the HEALing Communities Study research team. **WHOM TO CONTACT ABOUT THIS STUDY** During the study, if you have questions, concerns, or complaints about the study, please contact the Investigator at the telephone number listed on the first page of this consent document. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact: By mail: Study Participant Adviser Advarra IRB6940 Columbia Gateway Drive, Suite 110 Columbia, MD 21046 or call toll free: 877-992-4724 or by email: adviser@advarra.com

Please reference the following number when contacting the Study Participant Adviser: Pro00038088. DETAILED CONSENT: WHAT WILL YOU BE ASKED TO DO AND WHAT IS THE TOTAL AMOUNT OF TIME INVOLVED? A number of different research study activities will be involved during different phases of the study. If you agree to be part of the study, you will be asked to take part in a survey to ask you about the opioid-related services provided by jails in communities participating in HCS. The survey will take approximately 15 minutes to complete. Even if you agree to participate in the research study now, you may at any time decline to participate. Doing so will not affect your current work status, future advancement, or your relationship with the HEALing Communities Study research team.

WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? No physical risks are involved in this study. The risk of a breach in confidentiality of your study data is minimized by the procedures in place to protect your privacy. You will not be asked to provide personal information other than basic demographic information. Although we would like you to answer all the survey questions asked of you, you may choose not to answer questions without any negative consequences. There may be risks which are currently unforeseeable.

WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY? You will receive no direct benefits from participating in this research study. However, your participation could assist your community in examining procedures and improving services for individuals with opioid use disorder or at risk of opioid overdose. Your participation may also help your community by enhancing the process and communication among organizations involved.

IF YOU DON'T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER CHOICES? If you do not want to be in the study, there are no other choices except to not take part in the study.

WHAT WILL IT COST YOU TO PARTICIPATE? There is no cost to you to participate in the study.

WHO WILL SEE THE INFORMATION THAT YOU GIVE? We will make every effort to keep private all research study records that identify you to the extent allowed by law. Study data will be collected, managed, and analyzed by the four research sites and RTI International, the Data Coordinating Center located in North Carolina. Any data that are stored electronically will reside in a password-protected database on a secure server. Research records will be deidentified and stored using a secure participant identification number. These identification numbers will be used for combining data from various surveys and interviews, which will be important for analyzing the data. Your information will be combined with information from other people taking part in the study. The

study investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name. This means that absolute confidentiality cannot be guaranteed. We will publish the results of this study only in the aggregate, and you will not be identified directly or indirectly in study reports and presentations.

THIS RESEARCH STUDY IS COVERED BY A CERTIFICATE OF CONFIDENTIALITY from the National Institutes of Health. Study investigators with this Certificate may not disclose or use information or documents that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information or documents protected by this Certificate cannot be disclosed to anyone else who is not connected with the research study except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or neglect, harm to self or others, or communicable diseases), but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings; if you have consented to the disclosure; or if it is used for other scientific research, as allowed by federal regulations protecting research participants. The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the study that is needed for auditing or program evaluation by National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration, which are funding this study. You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this research study. **CAN YOU CHOOSE TO**

WITHDRAW FROM THE STUDY EARLY? You can choose to leave the study at any time. If you decide to take part in the study, you still have the right to decide at any time that you no longer want to continue. No one will think badly of you or treat you differently if you decide not to take part in this study. If you choose to leave the study early, data collected until that point will remain in the study database and may not be removed. The study investigator or sponsor can stop your participation at any time without your consent for the following reasons: If you fail to follow directions for participating in the study; If it is discovered that you do not meet the study requirements; If the study is canceled; or For administrative reasons. Any new important information that is discovered during the study

that may influence your willingness to continue participation in the study will be given to you. You may refuse to participate, or you may withdraw from the study at any time, without penalty. **WILL YOU RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY?** You will not receive compensation for completing the survey. **HOW WILL YOUR PRIVACY AND CONFIDENTIALITY BE PROTECTED?** We will take careful steps to keep your information confidential. All identifiable information (for example, your name) will be removed from the information collected in this study. We will make every effort to prevent anyone who is not on the research team from knowing that you gave us information, or what that information is. For example, your name will be kept separate from the information you give, and these two things will be stored in different places under lock and key. We will label your information with a code and will store the key separately from the master code list. Only select study staff will have access to the list that links the code to you. All research data will be kept in locked file cabinets. Computer files will be retained, and all electronic data will be password protected, stored on secure servers, and accessible only to the researchers on this study. **WILL YOUR INFORMATION BE STORED AND USED FOR FUTURE RESEARCH?** All identifiable information (for example, your name, employer, and contact information) will be removed from the information collected for this study. After we remove all identifiers, the information you provide during the study may be used for analysis or shared with other researchers without your additional informed consent. The deidentified information will be stored on secure servers at the research sites and the data coordinating center at RTI International during the study. We plan to store and share deidentified data from surveys and interviews for future research. Data collected or transmitted under this study will be maintained for at least 3 years. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. Researchers can use the stored information to research additional scientific questions. There is a risk that someone could get access to the stored information. Despite the security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now. **WHAT ELSE DO YOU NEED TO KNOW?** If you agree to take part in this study, you will be one of about 200 key jail employees to do so. The National Institute on Drug Abuse and the

Substance Abuse and Mental Health Services Administration are providing financial support for this study. A description of this clinical trial will be available on <http://www.clinicaltrials.gov/> as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. (descriptive)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='3'

Hello. My name is [name] and I work for the HEALing Communities Study (HCS) in your state. We are working with the National Institute on Drug Abuse (NIDA) and research sites in three other participating states to conduct the HEALing Communities Study. This study uses community engagement as a means to increase the use of evidence-based approaches with the goal of reducing opioid-related mortality by 40% over the course of the research study. We are conducting surveys to assess the provision of opioid use disorder related services provided by jails within counties participating in the HCS. The survey will last approximately 15 minutes. About 200 key employees within participating jails will be asked to complete this survey. Before we begin, I would like to review a few items: Participation. Your participation in this survey is voluntary and you can stop participating at any time without penalty or loss of benefits to which you are otherwise entitled. If at any time you are uncomfortable with any question, you can choose not to answer. This study is for research purposes only, there is no direct benefit and your only alternative is to not participate. There is no cost to you, and you will not be paid for taking part in this survey. We will not share your name and contact information with anyone outside of the research team. The study Investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name. This means that absolute confidentiality cannot be guaranteed. We are conducting this survey once a year and would like to contact you again to participate in future surveys. Benefits and Risk. You will receive no direct benefits from participating in this study. However, your responses may help us learn more about opioid overdose deaths in your community and potential reduction strategies. There are no physical risks

hcs22_consent_phone_y3

to participating in the study. You will not be asked to provide personal information other than basic demographics, and we will protect your confidentiality. There is a risk that someone could get access to the stored information. Despite the security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now. Reporting. As part of this study, we will write a report summarizing what we learned from these surveys. We will not use your name or any identifying information in the report. This report and study-related records may be shared with research staff at the HCS research sites, staff at the HCS Data Coordinating Center at RTI International, project staff at NIDA, and under certain circumstances, the Institutional Review Board (IRB). Future Research. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. After we remove all identifiers, we would like to securely store, use, and share these data for future research without additional informed consent. If you have questions, concerns or complaints about the study, please ask them now, or contact the study investigator. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact Advarra IRB. The toll-free number is 877-992-4724 and the email address is adviser@advarra.com. Please reference the following number when contacting the Study Participant Adviser: Pro00038088. Do you have any questions before we begin? (descriptive)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='1'

KEY INFORMATION We are asking you to choose whether or not to volunteer for the HEALing Communities Study funded by the National Institute on Drug Abuse and conducted by four academic institutions: Boston Medical Center, Columbia University, University of Kentucky, and The Ohio State University. This study uses community engagement as a means to increase the use of evidence-based approaches with the

hcs22_consent_web_y3

goal of reducing opioid-related mortality by 40% over the course of the research study. We are asking you to participate because as a key employee within jails associated with communities engaged in the HCS, you have information and opinions relevant to addressing the opioid epidemic. The details below may help you decide whether or not to participate. If you have questions, the contact information for the study investigator in charge of the study is provided above.

PARTICIPATION Participation in this survey should take approximately 15 minutes to complete and will involve about 200 other key jail employees. Your participation is voluntary. You may refuse at any time without penalty or loss of benefits to which you are otherwise entitled. Your decision will not affect your current employment status, future advancement, or your relationship with the HEALing Communities Study team.

COMPENSATION You will not receive compensation for completing this survey.

BENEFITS & RISKS You will receive no direct benefits from participating in this study. However, your responses may help us to learn more about opioid overdose deaths in your community and potential reduction strategies. There are no physical risks to participating in the study. You will not be asked to provide personal information other than basic demographics, and we will protect your confidentiality. There is a risk that someone could get access to the stored information. Despite the security measures and safeguards we will use, including not storing your name with your information, we cannot guarantee that your identity will never become known. There may be risks that at this time are unknown. As technology advances, there may be new ways of linking information back to you that we cannot foresee now. Having information collected from many people helps researchers identify trends and discover better ways to work with communities to reduce opioid overdoses. After we remove all identifiers, we would like to securely store, use, and share these data for future research without additional informed consent. There may be risks which are unforeseeable.

IF YOU DON'T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER CHOICES? There are no other choices except not to take part in the survey.

WHAT WILL IT COST YOU TO PARTICIPATE? There is no cost to you for participating in this study.

CAN YOU CHOOSE TO WITHDRAW FROM THE STUDY EARLY? If you decide to take part in the study, you still have the right to decide at any time that you no longer want to continue. No one will think badly of you or treat you differently if you decide not to take part in this study. If you choose to leave the study early, data collected until that point will remain in the study database and may not be removed. The study investigator or sponsor can stop your

participation at any time without your consent for the following reasons: If you fail to follow directions for participating in the study; If it is discovered that you do not meet the study requirements; If the study is canceled; or For administrative reasons. Any new important information that is discovered during the study that may influence your willingness to continue participation in the study will be given to you. You may refuse to participate, or you may withdraw from the study at any time, without penalty.

CONFIDENTIALITY We will not share your name and contact information with anyone outside of the research team. Your data will be assigned a unique, coded participant ID. Survey responses will be securely transmitted and stored at the HCS Data Coordinating Center at RTI International in North Carolina on a secure server and will contain personally identifiable information such as your name and email address. Your data will be combined with that of other participants and will only be reported in the aggregate. The study investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify you by name. **THIS STUDY IS COVERED BY A CERTIFICATE OF CONFIDENTIALITY** from the National Institutes of Health. The study investigators with this Certificate may not disclose or use information or documents that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information or documents protected by this Certificate cannot be disclosed to anyone else who is not connected with the study except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or neglect, harm to self or others, or communicable diseases), but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings; if you have consented to the disclosure; or if it is used for other scientific research, as allowed by federal regulations protecting research participants. The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the project that is needed for auditing or program evaluation by National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration, which are funding this project. You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this study. **WHOM TO CONTACT ABOUT THIS STUDY** During the study,

if you have questions, concerns, or complaints about the study, please contact the Investigator at the telephone number listed on the first page of this consent document. An institutional review board (IRB) is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact: By mail: Study Participant Adviser Advarra IRB6940 Columbia Gateway Drive, Suite 110 Columbia, MD 21046 or call toll free: 877-992-4724 or by email: adviser@advarra.com Please reference the following number when contacting the Study Participant Adviser: Pro00038088. A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. CONSENT I have read and understand this informed consent information. I have had an opportunity to ask questions if needed, and all of my questions have been answered to my satisfaction. I voluntarily agree to participate in this study until I decide otherwise. I do not give up any of my legal rights by agreeing to this consent information. Once you have read this consent form, if you choose to participate and you are 18 years of age or older, click on I agree to begin the survey. You may print this page for your records. (descriptive)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='2'

I have read and understand the information in this informed consent document. I have had an opportunity to ask questions and all of my questions have been answered to my satisfaction. I am 18 years of age or older, and voluntarily agree to participate in this study until I decide otherwise. I do not give up any of my legal rights by signing and dating this consent document. I will receive a copy of this signed and dated consent document. (descriptive)

hcs22_consent_language_inperson_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='3'

Do I have your consent to participate? [if a verbal "yes" then continue] (descriptive)

hcs22_consent_language_phone_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_consent_phone_2_y3]='1'

Once you have read this consent form, if you choose to participate and you are 18 years of age or older, click I agree to begin the study survey. You may print this page for your records. (descriptive)

hcs22_consent_language_web_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_mode_survey]='2'

(radio)

hcs22_consent_answer_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 1
Branching logic: [hcs22_mode_survey]='2' or [hcs22_mode_survey]='3' or [hcs22_consent_phone_2_y3]='1'

Choice value	Label	Frequency
1	I agree to participate	14
0	I do not agree to participate	0

Date of consent: (text)

consent_date_y3

Field type: text
Observations with this value left blank: 1
Number of unique values: 12
Branching logic: [hcs22_consent_answer_y3]='1'

7. Instrument: jail_survey_year_3

Version # (text)	hcs22_jail_version_y3
Field type: text Observations with this value left blank: 1 Number of unique values: 1	
HCS Annual Jail Survey (descriptive)	hcs22_title_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0	
<p>IMPORTANT DEFINITIONS This survey focuses on the following medications to treat opioid use disorder (MOUD, often referred to as Medication for Addiction Treatment, or MAT), as well as medications associated with the treatment of opioid withdrawal or overdose. Medications used to treat opioid use disorders: Buprenorphine: This is any partial agonist buprenorphine/buprenorphine-naloxone medication used for the treatment of opioid use disorders. Brand names include Suboxone®, Subutex®, Sublocade®, Zubsolv®, Bunavail®, Butrans®, Buprenex®, and Belbuca®. Methadone: This is the full agonist medication used for the treatment of opioid use disorders. Brand names include Methadose®, Dolophine®, Diskets®, and Methadone Intensol®. Naltrexone: This is a full antagonist medication used for the treatment of opioid use disorders. Brand names include: Vivitrol®, ReVia®, Adepend®, Depade®, Nalorex®, and Trexan® Classes or medications associated with the treatment of opioid withdrawal: Benzodiazepines: This class of drugs is often used to mitigate withdrawal symptoms after discontinuation of opioids in adults. Examples include: Chlordizepoxide, Clonazepam®, and Librium. Clonidine: This is used for multiple conditions, including mitigation of withdrawal symptoms after abrupt discontinuation of opioids in adults. Lofexidine: This is used to mitigate withdrawal symptoms after abrupt discontinuation of opioids in adults. Brand names include: Lucemyra® Medication associated with the treatment of an overdose: Naloxone: This medication is an opioid antagonist. It is used to rapidly reverse the effects of opiates and is available in both injectable and inhaled formulations. Brand names include: Narcan®, and</p>	screen1_y3

EVZIO® Some of these medications may also treat alcohol withdrawal and alcohol use disorders (e.g., Chlordiazepoxide, Librium, naltrexone); however, for the purpose of this survey we are asking about their use as medications for treatment of opioid use disorders (OUD). (descriptive)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

SAMPLED TIMEFRAME The purpose of this survey is to capture the services provided during a 12-month time period. The 12-month reporting period will be from July 1, 2021 to June 30, 2022. (descriptive) time_1_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Profile of People Detained in the Jail To get a picture of the profile of people detained in the jail, these questions are about people who were **DETAINED** in the jail between July 1, 2021 and June 30, 2022. By detained, we mean booked into the jail. When answering, please **INCLUDE** - Jails and other confinement facilities-including detention centers -intended for adults but sometimes holding juveniles, that are either privately owned and operated or administered by two or more governments (or a board composed of representatives from two or more governments). Temporary holding or lockup facilities if they are part of your combined function. Detainees held for other jurisdictions, including federal authorities, state prison authorities, American Indian or Alaska Native tribal governments, and other local jail jurisdictions. **EXCLUDE** - Services for individuals held by other jurisdictions. Services for individuals under community corrections or supervision who are **NOT** detained, including electronic monitoring, probation, parole, or diversion. Facilities that are exclusively used as temporary holding or lockup facilities, where detainees are generally held for less than 72 hours and not held beyond arraignment. (descriptive)

screen4_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

hcs22_state (descriptive)**lbl_hcs22_state_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Please select the state in which your facility is located. (radio)**hcs22_state_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 1

Choice value	Label	Frequency
1	Kentucky	0
2	Massachusetts	0
3	New York	0
4	Ohio	14

hcs22_role (descriptive)**lbl_hcs22_role_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

What is your role at the facility? (text)**hcs22_role_y3**

Required
Field type: text
Observations with this value left blank: 2
Number of unique values: 6

b1b_1 (descriptive)**lbl_b1b_1_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Does this jail house... ? (radio)**b1b_1_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 1

Choice value	Label	Frequency
1	Males only	0
2	Females only	0
3	Males and females	14
7000000	Prefer not to answer	0

c1a (descriptive)**lbl_c1a_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Between July 1, 2021 and June 30, 2022, how many persons were detained in the jail? By detained, we mean booked into the jail. (text)**c1a_y3**

Field type: text
Observations with this value left blank: 1
Number of unique values: 14

c1a1 (descriptive)**lbl_c1a1_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Between July 1, 2021 and June 30, 2022, how many of these detainees came in with opioid use problems? (VERY IMPORTANT, PLEASE AT A MINIMUM ESTIMATE) (text)**c1a1_y3**

Field type: text
Observations with this value left blank: 1
Number of unique values: 13

c1a2_u (descriptive)

lbl_c1a2_u_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [b1b_1_y3]='2' or [b1b_1_y3]='3'

Between July 1, 2021 and June 30, 2022, how many of these detainees with opioid use problems were pregnant women? (text)

c1a2_u_y3

Field type: text
Observations with this value left blank: 2
Number of unique values: 7
Branching logic: [b1b_1_y3]='2' or [b1b_1_y3]='3'

c1c_u (descriptive)

lbl_c1c_u_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Between July 1, 2021 and June 30, 2022, how many persons were released from the jail? (text)

c1c_u_y3

Field type: text
Observations with this value left blank: 1
Number of unique values: 14

b3 (descriptive)

lbl_b3_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Between July 1, 2021 and June 30, 2022, how many persons were detained in the jail from the county/community of [hcs22_poc_comm]? (VERY IMPORTANT, PLEASE AT A MINIMUM ESTIMATE) (text)

b3_y3

Field type: text
Observations with this value left blank: 1
Number of unique values: 14

b4 (descriptive) **lbl_b4_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Between July 1, 2021 and June 30, 2022, how many persons were detained in the jail on a per diem basis for another county, the State's Department of Corrections, or the Federal Bureau of Prisons or Federal Courts? (VERY IMPORTANT, PLEASE AT A MINIMUM ESTIMATE) (text) **b4_y3**

Field type: text
Observations with this value left blank: 1
Number of unique values: 9

ca1 (descriptive) **lbl_ca1_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Which model below best describes the healthcare delivery system in the jail? (radio) **ca1_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 4

Choice value	Label	Frequency
1	Direct services model (i.e.	2
2	Contracted model (i.e.	10
3	Hybrid model (combination of the above	1
4	Other	1

Please provide name of contracted vendor. (notes) **ca1a_y3**

Required
Field type: notes
Observations with this value left blank: 6

Number of unique values: 8
Branching logic: [ca1_y3] = '2'

Please provide name of contracted vendor. (notes) **ca1b_y3**

Required
Field type: notes
Observations with this value left blank: 14
Number of unique values: 1
Branching logic: [ca1_y3] = '3'

Please describe model. (notes) **ca1c_y3**

Required
Field type: notes
Observations with this value left blank: 14
Number of unique values: 1
Branching logic: [ca1_y3] = '4'

d1 (descriptive) **lbl_d1_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Does the jail have a screening protocol in place to identify people who likely have or may have opioid use problems? (radio) **d1_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 1

Choice value	Label	Frequency
1	Yes	14
0	No	0
7000000	Prefer not to answer	0

d1a1 (descriptive) **lbl_d1a1_y3**

Field type: descriptive

Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1_y3]<>'0'

Urinalysis to detect opioid use (radio)**d1a1_1_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	9
0	No	5
7000000	Prefer not to answer	0

Self-reported days of opioid use (radio)**d1a1_2_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 1
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	14
0	No	0
7000000	Prefer not to answer	0

Instrument/tool used to screen for possible opioid use disorder (OUD) (radio)**d1a1_3_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	8
0	No	6
7000000	Prefer not to answer	0

Instrument/tool used to screen for possible substance use disorder (SUD) (radio)**d1a1_4_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	7
0	No	7
7000000	Prefer not to answer	0

Clinical assessment to determine opioid use disorder diagnosis (radio)**d1a1_5_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	12
0	No	2
7000000	Prefer not to answer	0

Standardized questions during medical screening (radio)**d1a1_6_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3] <> '0'

Choice value	Label	Frequency
1	Yes	13
0	No	1
7000000	Prefer not to answer	0

Non-standardized inquiry during medical screening (radio)**d1a1_7_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3] <> '0'

Choice value	Label	Frequency
1	Yes	4
0	No	10
7000000	Prefer not to answer	0

d1a99_text (descriptive)**lbl_d1a99_text_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1_y3]<>'0'

Please list any other method used to help determine opioid use problems. (text)**d1a99_text_y3**

Field type: text
Observations with this value left blank: 1
Number of unique values: 6
Branching logic: [d1_y3]<>'0'

d1b1 (descriptive)**lbl_d1b1_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1_y3]<>'0'

Agency-created screening tool (radio)**d1b1_1_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	12
0	No	2
7000000	Prefer not to answer	0

State or regionally-developed screener/tools (radio)

d1b1_2_y3

Required
 Field type: radio
 Observations with this value left blank: 1
 Number of unique values: 2
 Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	7
0	No	7
7000000	Prefer not to answer	0

Addiction Severity Index (ASI) (radio)

d1b1_3_y3

Required
 Field type: radio
 Observations with this value left blank: 1
 Number of unique values: 2
 Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	0
0	No	13
7000000	Prefer not to answer	1

CAGE (Cut-down, Annoyed, Guilty, Eye-opener) (radio)

d1b1_4_y3

Required
 Field type: radio
 Observations with this value left blank: 1
 Number of unique values: 3
 Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	2
0	No	11
7000000	Prefer not to answer	1

DAST (Drug Abuse Screening Test) (radio) **d1b1_5_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	4
0	No	9
7000000	Prefer not to answer	1

Drug Use Screening Inventory (DUSI) (radio) **d1b1_6_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	0
0	No	13
7000000	Prefer not to answer	1

Global Appraisal of Individual Needs (GAIN) (radio) **d1b1_7_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	1
0	No	12
7000000	Prefer not to answer	1

TCU DS (Texas Christian University Drug Screen) (radio) **d1b1_8_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [d1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	0
0	No	13
7000000	Prefer not to answer	1

d1b99_text (descriptive) **lbl_d1b99_text_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [d1_y3]<>'0'

Please list any other instrument to screen for opioid use disorder/problems. (text) **d1b99_text_y3**

Field type: text
Observations with this value left blank: 2
Number of unique values: 3
Branching logic: [d1_y3]<>'0'

(radio) **d1b99_text_pnta_y3**

Required
Field type: radio
Observations with this value left blank: 14
Number of unique values: 1
Branching logic: [d1_y3]<>'0' and [d1b99_text_y3]=''

Choice value	Label	Frequency
7000000	Prefer not to answer	1

e1 (descriptive) lbl_e1_y3

Field type: descriptive
 Observations with this value left blank: 0
 Number of unique values: 0

Is there a standardized protocol in place to identify people who are withdrawing from or at risk of withdrawing from opioids? (radio) e1_y3

Required
 Field type: radio
 Observations with this value left blank: 1
 Number of unique values: 1

Choice value	Label	Frequency
1	Yes	14
0	No	0
7000000	Prefer not to answer	0

e1a1 (descriptive) lbl_e1a1_y3

Field type: descriptive
 Observations with this value left blank: 0
 Number of unique values: 0
 Branching logic: [e1_y3]<>'0'

Does the protocol include any of the following tools to screen for opioid withdrawal? (descriptive in matrix e1a1_text) e1a1_text_3

Field type: descriptive
 Observations with this value left blank: 0
 Number of unique values: 0
 Branching logic: [e1_y3]<>'0'

State or regionally developed screeners/tools (radio)**e1a1_1_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [e1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	7
0	No	7
7000000	Prefer not to answer	0

COWS (Clinical Opiate Withdrawal Scales) (radio)**e1a1_2_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [e1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	11
0	No	3
7000000	Prefer not to answer	0

Clinical observation of withdrawal symptoms (radio)**e1a1_3_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [e1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	13
0	No	1
7000000	Prefer not to answer	0

Self-report (radio)**e1a1_4_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2
Branching logic: [e1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	13
0	No	1
7000000	Prefer not to answer	0

e1a99_text (descriptive) **lbl_e1a99_text_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [e1_y3]<>'0'

Please list any other opioid withdrawal screener/tool. (text) **e1a99_text_y3**

Field type: text
Observations with this value left blank: 1
Number of unique values: 1
Branching logic: [e1_y3]<>'0'

e2 (descriptive) **lbl_e2_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Are any medications (excluding over the counter drugs) currently offered to address "withdrawal" from opioids? (radio) **e2_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2

Choice value	Label	Frequency
1	Yes	13
0	No	1

Choice value	Label	Frequency
7000000	Prefer not to answer	0

e2a1 (descriptive)
lbl_e2a1_y3

Field type: descriptive
 Observations with this value left blank: 0
 Number of unique values: 0
 Branching logic: [e2_y3]<>'0'

Benzodiazepine (including Chlordiazepoxide, Clonazepam, Librium) (radio)
e2a1_1_y3

Required
 Field type: radio
 Observations with this value left blank: 2
 Number of unique values: 2
 Branching logic: [e2_y3]<>'0'

Choice value	Label	Frequency
1	Yes	7
0	No	6
7000000	Prefer not to answer	0

Buprenorphine (including Suboxone, Subutex) (radio)
e2a1_2_y3

Required
 Field type: radio
 Observations with this value left blank: 2
 Number of unique values: 2
 Branching logic: [e2_y3]<>'0'

Choice value	Label	Frequency
1	Yes	10
0	No	3
7000000	Prefer not to answer	0

Lofexidine (including Lucemyra) (radio)
e2a1_3_y3

Required

Field type: radio
 Observations with this value left blank: 2
 Number of unique values: 3
 Branching logic: [e2_y3]<>'0'

Choice value	Label	Frequency
1	Yes	1
0	No	10
7000000	Prefer not to answer	2

Methadone (including Methadose, Dolophone, Diskets and Methadone Intensol) (radio) **e2a1_4_y3**

Required
 Field type: radio
 Observations with this value left blank: 2
 Number of unique values: 2
 Branching logic: [e2_y3]<>'0'

Choice value	Label	Frequency
1	Yes	2
0	No	11
7000000	Prefer not to answer	0

e2a99_text (descriptive) **lbl_e2a99_text_y3**

Field type: descriptive
 Observations with this value left blank: 0
 Number of unique values: 0
 Branching logic: [e2_y3]<>'0'

Please list any other medication offered to address withdrawal from opioids. (text) **e2a99_text_y3**

Field type: text
 Observations with this value left blank: 3
 Number of unique values: 4
 Branching logic: [e2_y3]<>'0'

(radio) **e2a99_text_pnta_y3**

Required
 Field type: radio

Observations with this value left blank: 14
 Number of unique values: 1
 Branching logic: [e2_y3]<>'0' and [e2a99_text_y3]="

Choice value	Label	Frequency
7000000	Prefer not to answer	1

f1 (descriptive) lbl_f1_y3

Field type: descriptive
 Observations with this value left blank: 0
 Number of unique values: 0

Is any type of medication assisted treatment (MAT) provided to detainees to treat their opioid use disorder (OUD)? (radio) f1_y3

Required
 Field type: radio
 Observations with this value left blank: 1
 Number of unique values: 2

Choice value	Label	Frequency
1	Yes	12
0	No	2
7000000	Prefer not to answer	0

f2 (descriptive) lbl_f2_y3

Field type: descriptive
 Observations with this value left blank: 0
 Number of unique values: 0
 Branching logic: [f1_y3]<>'0'

Is BUPRENORPHINE (e.g., Suboxone, Subutex) provided to detainees to treat their opioid use disorder (OUD)? (radio) f2_y3

Required
 Field type: radio
 Observations with this value left blank: 3
 Number of unique values: 2
 Branching logic: [f1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	9
0	No	3
7000000	Prefer not to answer	0

f2a2 (descriptive)
lbl_f2a2_y3

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: ([b1b_1_y3]='2' or [b1b_1_y3]='3') and [f1_y3]<>'0' and [f2_y3]<>'0'

Is BUPRENORPHINE provided to pregnant women only? (radio)
f2a2_y3

Required

Field type: radio

Observations with this value left blank: 6

Number of unique values: 3

Branching logic: ([b1b_1_y3]='2' or [b1b_1_y3]='3') and [f1_y3]<>'0' and [f2_y3]<>'0'

Choice value	Label	Frequency
1	Yes	2
0	No	6
1000000	Not applicable	1
7000000	Prefer not to answer	0

f2b2 (descriptive)
lbl_f2b2_y3

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [f1_y3]<>'0' and [f2_y3]<>'0'

Is BUPRENORPHINE used for induction and treatment during detainment? (radio)
f2b2_y3

Required

Field type: radio

Observations with this value left blank: 6

Number of unique values: 2

Branching logic: [f1_y3]<>'0' and [f2_y3]<>'0'

Choice value	Label	Frequency
1	Yes	6
0	No	3
7000000	Prefer not to answer	0

f2b4 (descriptive)
lbl_f2b4_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0' and [f2_y3]<>'0'

Is BUPRENORPHINE used for pre-release induction? (radio)
f2b4_y3

Required
Field type: radio
Observations with this value left blank: 6
Number of unique values: 3
Branching logic: [f1_y3]<>'0' and [f2_y3]<>'0'

Choice value	Label	Frequency
1	Yes	3
0	No	5
7000000	Prefer not to answer	1

f2b1 (descriptive)
lbl_f2b1_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0' and [f2_y3]<>'0'

Is BUPRENORPHINE used for continuity of care (maintenance of buprenorphine started in the community)? (radio)
f2b1_y3

Required
Field type: radio
Observations with this value left blank: 6
Number of unique values: 3
Branching logic: [f1_y3]<>'0' and [f2_y3]<>'0'

Is Extended Release Injectable BUPRENORPHINE (e.g., Sublocade) provided to detainees to treat their opioid use disorder (OUD)? (radio) e3_y3

Required
Field type: radio
Observations with this value left blank: 3
Number of unique values: 3
Branching logic: [f1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	2
0	No	9
7000000	Prefer not to answer	1

e3a (descriptive) lbl_e3a_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0' and [e3_y3]<>'0'

Between July 1, 2021 and June 30, 2022, how many detainees received Extended Release Injectable BUPRENORPHINE to treat their OUD? (text) e3a_y3

Field type: text
Observations with this value left blank: 13
Number of unique values: 2
Branching logic: [f1_y3]<>'0' and [e3_y3]<>'0'

(radio) e3a_pnta_y3

Required
Field type: radio
Observations with this value left blank: 14
Number of unique values: 1
Branching logic: ([f1_y3]<>'0' and [e3_y3]<>'0') and [e3a_y3]="

Choice value	Label	Frequency
7000000	Prefer not to answer	1

f5 (descriptive) lbl_f5_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0'

Is METHADONE (e.g., Methadose) provided to detainees to treat their OUD? (radio) f5_y3

Required
Field type: radio
Observations with this value left blank: 3
Number of unique values: 2
Branching logic: [f1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	5
0	No	7
7000000	Prefer not to answer	0

f5a2 (descriptive) lbl_f5a2_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: ([b1b_1_y3]='2' or [b1b_1_y3]='3') and [f1_y3]<>'0' and [f5_y3]<>'0' and [f5_y3] <> "

Is METHADONE provided to pregnant women only? (radio) f5a2_y3

Required
Field type: radio
Observations with this value left blank: 10
Number of unique values: 2
Branching logic: ([b1b_1_y3]='2' or [b1b_1_y3]='3') and [f1_y3]<>'0' and [f5_y3]<>'0' and [f5_y3] <> "

Choice value	Label	Frequency
1	Yes	1
0	No	4
1000000	Not applicable	0
7000000	Prefer not to answer	0

f5b2 (descriptive)**lbl_f5b2_y3**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [f1_y3]<>'0' and [f5_y3]<>'0' and [f5_y3] <> "

Is METHADONE used for induction and treatment during detainment? (radio)**f5b2_y3**

Required

Field type: radio

Observations with this value left blank: 10

Number of unique values: 1

Branching logic: [f1_y3]<>'0' and [f5_y3]<>'0' and [f5_y3] <> "

Choice value	Label	Frequency
1	Yes	0
0	No	5
7000000	Prefer not to answer	0

f5b4 (descriptive)**lbl_f5b4_y3**

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [f1_y3]<>'0' and [f5_y3]<>'0' and [f5_y3] <> "

Is METHADONE used for pre-release induction? (radio)**f5b4_y3**

Required

Field type: radio

Observations with this value left blank: 10

Number of unique values: 1

Branching logic: [f1_y3]<>'0' and [f5_y3]<>'0' and [f5_y3] <> "

Choice value	Label	Frequency
1	Yes	0
0	No	5
7000000	Prefer not to answer	0

f5e (descriptive) **lbl_f5e_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0' and [f5_y3]<>'0' and [f5_y3] <> "

Between July 1, 2021 and June 30, 2022, how many detainees received METHADONE to treat their OUD? (text) **f5e_y3**

Field type: text
Observations with this value left blank: 10
Number of unique values: 5
Branching logic: [f1_y3]<>'0' and [f5_y3]<>'0' and [f5_y3] <> "

f8 (descriptive) **lbl_f8_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0'

Is injectable or oral NALTREXONE (e.g., Vivitrol, ReVia, Depade) provided to detainees to treat their OUD? (radio) **f8_y3**

Required
Field type: radio
Observations with this value left blank: 3
Number of unique values: 2
Branching logic: [f1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	10
0	No	2
7000000	Prefer not to answer	0

f8b2 (descriptive) **lbl_f8b2_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0' and [f8_y3]<>'0' and [f8_y3] <> "

Is injectable or oral NALTREXONE (e.g., Vivitrol, ReVia, Depade) used for induction and treatment during detainment? (radio) f8b2_y3

Required
Field type: radio
Observations with this value left blank: 5
Number of unique values: 2
Branching logic: [f1_y3]<>'0' and [f8_y3]<>'0' and [f8_y3] <> "

Choice value	Label	Frequency
1	Yes	9
0	No	1
7000000	Prefer not to answer	0

f8b3 (descriptive) lbl_f8b3_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0' and [f8_y3]<>'0' and [f8_y3] <> "

Is injectable or oral NALTREXONE (e.g., Vivitrol, ReVia, Depade) used for pre-release induction? (radio) f8b3_y3

Required
Field type: radio
Observations with this value left blank: 5
Number of unique values: 1
Branching logic: [f1_y3]<>'0' and [f8_y3]<>'0' and [f8_y3] <> "

Choice value	Label	Frequency
1	Yes	10
0	No	0
7000000	Prefer not to answer	0

f8e (descriptive) lbl_f8e_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3]<>'0' and [f8_y3]<>'0' and [f8_y3] <> "

Between July 1, 2021 and June 30, 2022, how many detainees received NALTREXONE to treat their OUD? (text) f8e_y3

Field type: text
Observations with this value left blank: 8
Number of unique values: 7
Branching logic: [f1_y3]<>'0' and [f8_y3]<>'0' and [f8_y3] <> "

(radio) f8e_pnta_y3

Required
Field type: radio
Observations with this value left blank: 12
Number of unique values: 1
Branching logic: ([f1_y3]<>'0' and [f8_y3]<>'0' and [f8_y3] <> ") and [f8e_y3]="

Choice value	Label	Frequency
7000000	Prefer not to answer	3

j2 (descriptive) lbl_j2_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Does the jail have naloxone available for staff to reverse opioid overdoses within the jail? (radio) j2_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 1

Choice value	Label	Frequency
1	Yes	14
0	No	0
7000000	Prefer not to answer	0

j4 (descriptive) lbl_j4_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Does the jail provide training to detainees on how to use naloxone to reverse an overdose? (radio) **j4_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2

Choice value	Label	Frequency
1	Yes	7
0	No	7
7000000	Prefer not to answer	0

j5 (descriptive) **lbl_j5_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Does the jail provide naloxone kits at release to detainees? (radio) **j5_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2

Choice value	Label	Frequency
1	Yes	6
0	No	8
7000000	Prefer not to answer	0

j5a1 (descriptive) **lbl_j5a1_y3**

Field type: descriptive
Observations with this value left blank: 0

Number of unique values: 0
Branching logic: [j5_y3] <> '0'

Does the jail provide naloxone kits at release to all detainees? (radio) **j5a1_y3**

Required
Field type: radio
Observations with this value left blank: 9
Number of unique values: 2
Branching logic: [j5_y3] <> '0'

Choice value	Label	Frequency
1	Yes	2
0	No	4
7000000	Prefer not to answer	0

j5a2 (descriptive) **lbl_j5a2_y3**

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [j5a1_y3] <> '1' and [j5_y3] <> '0'

Does the jail provide naloxone kits at release to only detainees with substance use disorder? (radio) **j5a2_y3**

Required
Field type: radio
Observations with this value left blank: 11
Number of unique values: 2
Branching logic: [j5a1_y3] <> '1' and [j5_y3] <> '0'

Choice value	Label	Frequency
1	Yes	2
0	No	2
7000000	Prefer not to answer	0

j5a3 (descriptive) **lbl_j5a2_y4**

Field type: descriptive
Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [j5a2_y3] <> '0' and [j5_y3] <> '0' and [j5a1_y3] <> '1'

Does the jail provide naloxone kits at release to only detainees with opioid use disorder? (radio)

j5a3_y3

Required

Field type: radio

Observations with this value left blank: 13

Number of unique values: 1

Branching logic: [j5a2_y3] <> '0' and [j5_y3] <> '0' and [j5a1_y3] <> '1'

Choice value	Label	Frequency
1	Yes	2
0	No	0
7000000	Prefer not to answer	0

j6a (descriptive)

lbl_j6a_y3

Field type: descriptive

Observations with this value left blank: 0

Number of unique values: 0

Branching logic: [j5_y3]<>'0' and [j5_y3] <> "

Between July 1, 2021 and June 30, 2022, approximately how many inmates received kits upon release? (text)

j6a_y3

Field type: text

Observations with this value left blank: 12

Number of unique values: 3

Branching logic: [j5_y3]<>'0' and [j5_y3] <> "

(radio)

j6a_pnta_y3

Required

Field type: radio

Observations with this value left blank: 12

Number of unique values: 1

Branching logic: [j5_y3]<>'0' and [j5_y3] <> " and [j6a_y3]="

Choice value	Label	Frequency
7000000	Prefer not to answer	3

k1a (descriptive) lbl_k1a_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

a. Induct (start) detainees on MAT? (radio) k1a_a_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3

Choice value	Label	Frequency
1	Yes	9
0	No	4
7000000	Prefer not to answer	1

b. Schedule appointments with MAT providers in the community? (radio) k1a_b_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2

Choice value	Label	Frequency
1	Yes	10
0	No	4
7000000	Prefer not to answer	0

c. Provide assistance completing intake paperwork for quick access to MAT provider in the community? (radio) k1a_c_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3

Choice value	Label	Frequency
1	Yes	8
0	No	5
7000000	Prefer not to answer	1

d. Facilitate exchange of key information with the MAT provider in the community? (radio) k1a_d_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2

Choice value	Label	Frequency
1	Yes	8
0	No	6
7000000	Prefer not to answer	0

e. Provide detainees with the name(s) of MAT providers in their community of release? (radio) k1a_e_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2

Choice value	Label	Frequency
1	Yes	9
0	No	5
7000000	Prefer not to answer	0

f. Coordinate MAT services with parole/probation? (radio) k1a_f_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3

Choice value	Label	Frequency
1	Yes	9

Choice value	Label	Frequency
0	No	4
7000000	Prefer not to answer	1

g. Assist with reactivating and/or applying for Medicaid, Veterans benefits or other types of insurance for payment of MAT? (radio) **k1a_g_y3**

Required
 Field type: radio
 Observations with this value left blank: 1
 Number of unique values: 3

Choice value	Label	Frequency
1	Yes	7
0	No	6
7000000	Prefer not to answer	1

h. Connect detainees to a peer mentor/navigator/recovery coach? (radio) **k1a_h_y3**

Required
 Field type: radio
 Observations with this value left blank: 1
 Number of unique values: 2

Choice value	Label	Frequency
1	Yes	8
0	No	6
7000000	Prefer not to answer	0

k1z_text (descriptive) **lbl_k1z_text_y3**

Field type: descriptive
 Observations with this value left blank: 0
 Number of unique values: 0

Please list the other things staff do to facilitate linkage to MAT during the month prior to release. (text) **k1z_text_y3**

Field type: text
Observations with this value left blank: 2
Number of unique values: 5

(radio)		k1z_text_pnta_y3
Required		
Field type: radio		
Observations with this value left blank: 14		
Number of unique values: 1		
Branching logic: [k1z_text_y3]="		
Choice value	Label	Frequency
7000000	Prefer not to answer	1

k2a (descriptive)		lbl_k2a_y3
Field type: descriptive		
Observations with this value left blank: 0		
Number of unique values: 0		

a. Provide or arrange transportation to MAT provider in the community? (radio)		k2a_a_y3
Required		
Field type: radio		
Observations with this value left blank: 1		
Number of unique values: 2		
Choice value	Label	Frequency
1	Yes	6
0	No	8
7000000	Prefer not to answer	0

b. Provide transportation (i.e. bus cards/tokens) home for detainee? (radio)		k2a_b_y3
Required		
Field type: radio		
Observations with this value left blank: 1		
Number of unique values: 2		

Choice value	Label	Frequency
1	Yes	4
0	No	10
7000000	Prefer not to answer	0

c. Provide a bridge supply of multiple doses/days of MAT? (radio) k2a_c_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3

Choice value	Label	Frequency
1	Yes	2
0	No	11
7000000	Prefer not to answer	1

d. Provide written prescriptions for MAT? (radio) k2a_d_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3

Choice value	Label	Frequency
1	Yes	4
0	No	9
7000000	Prefer not to answer	1

e. Provide detainees with a list of MAT providers in their community of release? (radio) k2a_e_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3

Choice value	Label	Frequency
1	Yes	6
0	No	7

Choice value	Label	Frequency
7000000	Prefer not to answer	1

f. Connect detainee to a peer mentor/navigator/recovery coach? (radio) k2a_f_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 2

Choice value	Label	Frequency
1	Yes	7
0	No	7
7000000	Prefer not to answer	0

k2z_text (descriptive) lbl_k2z_text_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

Please list the other things staff do to facilitate linkage to MAT on the day of the release. (text) k2z_text_y3

Field type: text
Observations with this value left blank: 1
Number of unique values: 4

COVIDINTRO (descriptive in matrix lbl_covidintro) lbl_covidintro_3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

The COVID-19 pandemic required a major crisis response and policy change in order to reduce the risks of transmission and to promote health of those who were detained. This crisis response led to the release of many people in county jails. The next questions are about how the COVID-19 covidintro_3

pandemic policy changes impacted your jail, including population census. Please provide us with your best estimate if possible. (descriptive in matrix covidintro)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

O1 (descriptive) lbl_o1_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

When COVID-19 pandemic policy changes were implemented, were individuals released from your jail because of health and safety protocol changes and considerations? (radio) o1_y3

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3

Choice value	Label	Frequency
1	Yes	5
0	No	8
8000000	Don't know	1
7000000	Prefer not to answer	0

O2 (descriptive) lbl_o2_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o1_y3] = '1'

About how many individuals were released from your jail because of COVID-19 pandemic policy changes between July 1, 2021 and June 30, 2022? (text) o2_y3

Field type: text
Observations with this value left blank: 14

Number of unique values: 1
Branching logic: [o1_y3] = '1'

(radio)		o2_dk_pnta_y3
Required		
Field type: radio		
Observations with this value left blank: 11		
Number of unique values: 1		
Branching logic: [o1_y3] = '1' and [o2_y3] = "		
Choice value	Label	Frequency
8000000	Don't know	4
7000000	Prefer not to answer	0

O3 (descriptive)	lbl_o3_y3
Field type: descriptive	
Observations with this value left blank: 0	
Number of unique values: 0	
Branching logic: [o1_y3] <> '0'	

(radio)		o3_dk_pnta_y3
Required		
Field type: radio		
Observations with this value left blank: 9		
Number of unique values: 2		
Branching logic: [o1_y3] <> '0' and [o3_y3] = "		
Choice value	Label	Frequency
8000000	Don't know	5
7000000	Prefer not to answer	1

O4 (descriptive)	lbl_o4_y3
Field type: descriptive	
Observations with this value left blank: 0	
Number of unique values: 0	
Branching logic: [o1_y3] <> '0' and [f1_y3] = '1'	

(radio)

o4_dk_pnta_y3

Required
Field type: radio
Observations with this value left blank: 9
Number of unique values: 2
Branching logic: [o1_y3] <> '0' and [f1_y3] = '1' and [o4_y3] = "

Choice value	Label	Frequency
8000000	Don't know	5
7000000	Prefer not to answer	1

O5 (descriptive)

lbl_o5_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [f1_y3] = '1'

Were individuals in your facility permitted to stay on MOUD during the COVID-19 pandemic? (radio)

o5_y3

Required
Field type: radio
Observations with this value left blank: 3
Number of unique values: 2
Branching logic: [f1_y3]='1'

Choice value	Label	Frequency
1	Yes	10
0	No	0
8000000	Don't know	2
7000000	Prefer not to answer	0

O5-2 (descriptive)

lbl_o5_2_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o1_y3] <> '0'

Were all persons who were released from jail as a

o5_2_y3

**result of COVID-19 pandemic policy changes
offered routine reentry planning services? (radio)**

Required
Field type: radio
Observations with this value left blank: 9
Number of unique values: 3
Branching logic: [o1_y3]<>'0'

Choice value	Label	Frequency
1	Yes	1
0	No	3
8000000	Don't know	2
7000000	Prefer not to answer	0

O5a (descriptive) lbl_o5a_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o5_2_y3] = '0' and [o1_y3] <> '0'

O5b (descriptive) lbl_o5b_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o5_2_y3] = '1' and [o1_y3] <> '0'

O6 (descriptive) lbl_o6_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0

**Between July 1, 2021 and June 30, 2022, since
COVID-19 pandemic policy changes has your
inmate population decreased, increased or stayed
about the same? (radio) o6_y3**

Required
Field type: radio
Observations with this value left blank: 1
Number of unique values: 3

Choice value	Label	Frequency
1	Decreased	5
2	Increased	1
3	Stayed about the same	8
8000000	Don't know	0
7000000	Prefer not to answer	0

O6a (descriptive)
lbl_o6a_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o6_y3] = '1'

Between July 1, 2021 and June 30, 2022, by what percentage on average has your jail's monthly inmate population decreased? (text)

o6a_y3

Field type: text
Observations with this value left blank: 12
Number of unique values: 3
Branching logic: [o6_y3] = '1'

(radio)
o6a_dk_pnta_y3

Required
Field type: radio
Observations with this value left blank: 13
Number of unique values: 1
Branching logic: [o6_y3] = '1'

Choice value	Label	Frequency
8000000	Don't know	2
7000000	Prefer not to answer	0

O6b (descriptive)
lbl_o6b_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [o6_y3] = '2'

(radio)

o6b_dk_pnta_y3

Required
Field type: radio
Observations with this value left blank: 14
Number of unique values: 1
Branching logic: [o6_y3] = '2' and [o6b_y3] = "

Choice value	Label	Frequency
8000000	Don't know	1
7000000	Prefer not to answer	0

n7 (descriptive)

lbl_n7_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y3]='3'

Recent bail reform legislation in New York ended the use of cash bail for most misdemeanors and Class E felonies. This reform led to the release of many people in county jails who were no longer eligible to be held on bail as well as other impacts on arrests and arraignment. The next questions are about how bail reform legislation impacted your jail, including population census. Please provide us with your best estimate if possible. (descriptive)

bailintro_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y3]='3'

n1 (descriptive)

lbl_n1_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y3]='3'

n2 (descriptive)

lbl_n2_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y3]='3' AND [n1_y3]<>'0' AND [n2_y3]=''

n3 (descriptive)	lbl_n3_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state_y3]='3' AND [n1_y3]<>'0'	

n4 (descriptive)	lbl_n4_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state_y3]='3' AND [n1_y3]<>'0'	

n5 (descriptive)	lbl_n5_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state_y3]='3' AND [n1_y3]<>'0'	

n5a (descriptive)	lbl_n5a_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state_y3]='3' AND [n5_y3]='0' and [n1_y3]<>'0'	

n5b (descriptive)	lbl_n5b_y3
Field type: descriptive Observations with this value left blank: 0 Number of unique values: 0 Branching logic: [hcs22_state_y3]='3' AND [n5_y3]='1' and [n1_y3]<>'0'	

Bail reforms were expected to change the number and types of persons being held in jail.	n6_desc_y3
---	-------------------

(descriptive)

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y3]='3'

n6 (descriptive)

lbl_n6_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y3]='3'

n6a (descriptive)

lbl_n6a_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y3]='3' and [n6_y3]='1'

n6b (descriptive)

lbl_n6b_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0
Branching logic: [hcs22_state_y3]='3' and [n6_y3]='2'

That was the last question. Thank you for your time. This survey contains multiple items adapted with permission from Scott, C.K, & Dennis, M.L. (2019). Justice Community Opioid Innovation Network (JCOIN): Jail Interview Protocol. Chicago, IL: Chestnut Health Systems. (descriptive)

endsurvey_y3

Field type: descriptive
Observations with this value left blank: 0
Number of unique values: 0